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IUD : Intrauterine Death
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MVA : Manual Vacuum Aspiration
TAT : Trans Abdominal Tubectomy
ST : Sterilisation
MTP : Medical Termination of Pregnancy
CBC : Complete blood count
RFT : Renal function test
LFT : Liver function test
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1INTRODUCTION
Pregnant mother with heart disease is a challenge to both obstetrician
and the woman. It could be associated with an unfavourable maternal and
perinatal outcome. It requires special care to prevent or decrease the
maternal mortality and morbidity.
In our country most women are concealing their heart disease due to
local problems and marital problems, even after the diagnosis many
patients do not follow the instructions given by the obstetrician.
Gestational hypertension, gestational diabetes and anaemia are the added
problems which are more common in our country.
In developing countries, Rheumatic fever and its sequelae still
remain the most common etiological factor for heart disease and it is due to
streptococcal infection in country side. In our institution, RHD( Rheumatic
heart disease ) is the major cause of heart disease during pregnancy. In
women with known cardiac diseases, cardiac status must be optimized and
a more desirable planned elective safe delivery should be scheduled.
2AIMS OF STUDY
1. To know the incidence of heart disease among pregnant mothers
during study period
2. To know the various aetiological factors for heart disease.
3. To know the possible prognostic factors which facilitate formulation
of guidelines for a safe motherhood.
4. To know the impacts of pregnancy on heart disease.
5. To know the impacts of heart disease on pregnancy.
6. To know the role of medical termination of pregnancy and method
of sterilisation in patients with heart disease.
7. To know the maternal outcome according to EF.
8. To know the overall maternal and perinatal outcome.
3REVIEW OF LITERATURE
The foremost initial study was done by Hamilton and Thompson at
the Boston hospital between 1921 & 1938 on heart disease complicating
pregnancy.
Subsequently a study on heart disease complicating pregnancy
during 1950 was conducted by Sudhir Bose Calcutta and Masoni Bombay.
They concluded the incidence ranging from 0.2 to 0.97%.1
According to CDC- Heart diseases is the main cause of death in
women who are 25-44 years as described by Kung and colleagues 2008.2
Chang and associates described about cardiomyopathy being responsible
for 8% of 4200 delivery related death in US 1991-1999. From Brazil
Avilaand co-workers 20033 reported the maternal mortality rate to be 2.7%
in 1000 pregnancies complicated by heart disease.
Cardiac disease complicates>1% of all pregnancies and it is the
leading indirect cause of maternal death in 20% of all cases described by
Simpson 20126 and Berg 2010 study. A study conducted by Small 20124
reported that cardiac disease was responsible for significant maternal
morbidity and obstetric intensive care unit admission. Fryar 20125 gave a
statistics that almost50% of adults aged 20 and above have at least one risk
factor for cardiovascular diseases like obesity, Hypertension, Diabetes7.6%
4of severe obstetric morbidities are caused by cardiac disease as represented
in a US study conducted by Callaghan & co-workers in 2008.
A study by Barnes6 in the queen charlotte hospital on 1192 patients
with heart disease delineate that rheumatic heart disease was seen in 88.2%
and congenital heart disease in 11.8%. Mcfaul-1988, Bitsch and co-
workers-1989 described that 50% were suffering from congenital heart
disease . A study conducted by Tan and De Sweit 19987 reported that only
12% had rheumatic heart disease. Brickner and associates delineated that
progress in surgical methods and development in medical management will
cause increase in the number of women with congenital heart disease
reaching pregnancy.
Martin and co-workers 1999 described that heart disease remains to
be the third most common cause of maternal death.
HAEMODYNAMIC CHANGES IN PREGNANCY
The heart and circulation undergoes various physiological
adaptations during pregnancy, delivery and puerperium. These marked
changes have an intense effect on heart disease in the pregnant mother.
Changes in cardiac function become readily seen during the first 8 weeks
of pregnancy as described by Hibbard 20148. Capeless and Clapp 19899
have described that there is 50% increase in cardiac output by 8 weeks of
pregnancy. Systolic and diastolic blood pressure is decreased during 6-7
5weeks of pregnancy as described by Mahendru 201210. The resting pulse
rate is increased by 10 beats. Cardiac output in lateral recumbent position
is increased in early pregnancy as reported by Duvekot and associated
1993, Mebie and colleagues-1994. Mild pericardial effusion and increased
cardiac silhouette was described by Enein and co-workers 198711.  Cutforth
and Mac Donald 196612 used phonocardiography and documented an
exaggerated splitting of first heart sound with increasedloudness of both
components.There changes are more profound in multiple pregnancies as
reported by Kametas and associated 200313 Pregnant uterus compresses
venous return from lower extremities and may also compress the aorta as
described by Bieniare 1969
A great valuable study conducted by Clark and associated 198914 to
measure hemodynamic function in later pregnancy - right heart
catheterisation was done in 10 healthy nulliparous women at 35-38 weeks
and again 11 to 13 weeks postpartum. It described normal haemodynamic
values in late pregnancy. Yuan and co-workers 2006 described the normal
morphological and functional echo changes associated with pregnancy.
DIAGNOSIS OF HEART DISEASES
The normal physiological changes of pregnancy can produce
symptoms and signs that may be difficult to be differentiated from heart
disease. Melchiorre and associated 201115 described the relationship
6between undiagnosed maternal cardiac abnormalities and mid trimester
uterine artery Doppler resistance indices. Atrial and ventricular premature
contractions are frequent during pregnancy as reported by Carruth 1981.
Savu 201216 and Vitrarelli 2011 have described the normal
echocardiographicparameters for pregnancy. Limacher 1985 organised
studies on 2D echo and pulsed doppler echo.
SYMPTOMS AND SIGNS:
Symptoms & Signs in normal pregnancy that mimic heart disease
Symptoms
 Dyspnoea
 Edema
Signs
 Low blood pressure
 Increased PR & RR
 Cardiac impulse more diffuse
 Jugular veins may be distended
 Heart sounds are often more pronounced.
 Ejection systolic murmur of grade 2/6
 Venuos hum over the jugular vein.
7X-Ray
 Cardiomegaly
ECG
 ST depression & T wave changes
 LAD (Left Axis Deviation)
ECHO
 Minimal pericardial effusion
Symptoms & signs in heart disease
Symptoms
 Progressive dyspnoea or orthopnoea
 Nocturnal cough
 Hemoptysis
 Syncope
 Chest pain
Signs
 Cyanosis
 Clubbing of fingers
 Persistent neck vein distension
 Systolic murmur grade 3/6 or greater.
8 Diastolic murmur
 Cardiomegaly
 Persistent arrhythmias
 Persistent split second sound
 Criteria for pulmonary Hypertension
o Left parasternal lift
o Loud P2
CLASSIFICATION
This classification of New York Heart Association was first
published in 1928 and revised for the eighth time in 1978, based on past
and present disability and is uninfluenced by physical signs. Siu and
associated 2001b18 developed a scoring system based on risk factor. Two
studies by Khariy and colleagues 200619, Stangl 200820were conducted
using the risk criteria.
9TABLE-1 NEW YORK HEART ASSOCIATION FUNCTIONAL
CLASSIFICATION OF CARDIAC DISEASE
Grade I Patients have no limitations of physical exercise; ordinary
activity does not cause undue fatigue, palpitations, dyspnoea or
angina.
Grade II Patients have slight limitations of physical exercise; ordinary
activity causes undue fatigue, palpitations, dyspnoea or angina.
Grade III Patients have marked limitations of physical activity, less than
ordinary activity causes symptoms.
Grade IV Patients have an inability to carry on physical activity without
symptoms.
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TABLE-2 MODIFIED WHO CLASSIFICATION OF MATERNAL
CARDIOVASCULAR RISK
WHO RISK Class I
Uncomplicated, small or mild
 Pulmonary stenosis
 Patent ductus arteriosus
 MVP, mitral valve prolapse
Successfully repaired simple lesions (atrial or ventricular septal defect,
patent ductus arteriosus, anomalous pulmonary venous drainage)
Isolated atrial or ventricular ectopic beats
WHO Risk Class II (if otherwise well and uncomplicated)
Unoperated atrial or ventricular septal defect
Repaired tetralogy of Fallot
Most arrhythmias
WHO risk class II-III (depending on individual)
Mild left ventricular systolic function impairment
Hypertrophic cardiomyopathy
Native or tissue valvular heart disease not considered WHO I or IV
Marfan’s syndrome without aortic dilatation
Aorta <45mm in aortic disease associated with bicuspid aortic valve
Repaired coarctation
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WHO Risk Class III
Mechanical valve
Systemic right ventricle
Fonton circulation
Cyanotic heart disease (unrepaired)
Other complex congenital heart disease
Aortic dilatation 40-45 mm in Marfan’s syndrome
Aortic dilation 45-50 mm in aortic disease associated with bicuspid aortic
valve
WHO Risk Class IV (Pregnancy contraindicated)
Pulmonary arterial hypertension of any cause
Severe systemic ventricular dysfunction (LVEF <30%, NYHA III-IV)
Previous peripartum cardiomyopathy with any residual impairment of left
ventricular function
Severe mitral stenosis with aortic root dilatation>45mm
Aortic dilatation>50mm in aortic disease associated with bicuspid aortic
valve
Native severe coarctation
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TABLE-3 MODIFIED WHO CLASSIFICATION OF MATERNAL
CARDIOVASCULAR RISK: PRINCIPLES
Risk Class Risk by Medical Condition
I No detectable increased risk of maternal mortality and
no/mild increase in morbidity.
II Small increased risk of maternal mortality or moderate
increase in morbidity.
III Significantly increased risk of maternal mortality or severe
morbidity. Expert counselling required. If pregnancy is
decided upon, intensive specialist cardiac and obstetric
monitoring needed throughout pregnancy, childbirth and
puerperium.
IV Extremely high risk of maternal mortality or severe
morbidity; pregnancy contraindicated. If pregnancy
occurs,termination should be discussed. If pregnancy
continues, care as for class III.
13
TABLE-4 PREDICTORS OF MATERNAL CARDIOVASCULAR
EVENTS AND RISK SCORE FROM THE CARPREG STUDY
Prior cardiac event (heart failure, transient ischaemic attack, stroke before
pregnancy or arrhythmia)
Baseline NYHA functional class > II or cyanosis
Left heart obstruction (mitral valve area <2cm2, aortic valve
area<1.5cm2, peak LV outflow tract gradient >30 mmHg by
echocardiography)
Reduced systemic ventricular systolic function (ejection fraction <40%)
CARPREG risk score:For each above mentioned CARPREG predictor
that is present, a point is assigned. Risk estimation of cardiovascular
maternal complications
0 point 5%
1 point 27%
>1 point 75%
PRECONCEPTIONAL COUNSELLING
Women with cardiac conditions who desire or anticipate pregnancy
should be offered preconceptional counselling. The evolution of risk
provides a basis to explain to the patient the need for extensive testing
during pregnancy, increased frequency of office visits, need for prolonged
14
hospitalization and in some cases the need for surgical or medical
procedures before pregnancy. Risk assessment is also useful to determine
the type of facility where the patient should go for her delivery.
The need for induction of labour, shortening of the second stage of
labour, methods of anaesthesia used during labour and delivery,
endocarditis prophylaxis and anticoagulation therapy should also be a part
of the consultation. Patients with Eisenmenger syndrome, severe
pulmonary hypertension, severe left-sided obstructive lesions, and women
with Marfan syndrome and dilated aortic roots should be informed about
the high risk of maternal mortality and be counselled to consider avoiding
pregnancy and to choose adoption or other methods to have a family.
RHEUMATIC HEART DISEASE
Mitral stenosis
The normal Mitral valve surface area is 4cm2. Mitral stenosis
symptoms develops usually when the mitral valve surface area is less than
2.5cm2as described by Desai 200021. Due to tight stenosis left atrium is
dilated and left atrial pressure is chronically elevated resulting in fixed
cardiac output and development of pulmonary hypertension described by
Carabello and Crawfird 199722. A study conducted by Caulin  Glaser and
Setaco 199923 suggests that one-fourth of pregnant women with mitral
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stenosis develop cardiac failure for the first time in pregnancy. Rheumatic
endocarditis causes 75% of mitral stenosis.
Atrial tachycardia and atrial fibrillation are common in mitral
stenosis. Atrial fibrillation predisposes to mural thrombus and
cerebrovascular embolization that can cause stroke described by Hameed
and associate 200524.
Limited physical work, decreased sodium intake and addition of
diuretics described by Siva and Shah 200525. Alkasab and associates 1990,
Maxwell 2010 described the use of β blockers (usually given to decrease
the cardiac response during work and anxiety) in pregnancy.
Atrial fibrillation new onset - IV verapamil, electro cardio version,
chronic – digoxin β blocker or calcium channel blocker, persistent atrial
fibrillation – heparin.
Hameed and co-workers described heparin for severe stenosis even
if there is a sinus rhythm. During labour, pain relief by epidural analgesia,
back rest, anxiolytic measures and IV fluid restriction to 75ml/hr are
necessary to avoid cardiac failure. Clark and colleague hypothesize
increase in pulmonary capillary wedge pressure during immediate
postpartum due to loss of the low resistance placental circulation along
with auto transfusion from lower extremities, increase in preload may lead
to increase Pulmonary capillary wedge pressure and pulmonary oedema so
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to avoid volume overload as described by Ramin and Gilstrap 1999.
Pregnancy outcomes were studied by Hammed 2001 and sawhney 200326
directly related with the degree of valvular stenosis.
AORTIC STENOSIS
Next to mitral stenosis, aortic stenosis is the common cardiac lesion.
The most common lesion is bicuspid aortic valve - Friedman and co-
workers 200827. Stenosis reduces the normal 2-3 cm aortic orifice and
creates resistance to ejection. Reduction in the valve area <1cm, pressure
gradient <5mmHg produces obstruction to flow and a progressive overload
on the left ventricle described by Carabello 200228, Roeder 201129. During
pregnancy some factors like haemorrhage, regional anaesthesia in labour
and vena caval occlusion by gravid uterus acutely decreases the preload
further and aggravates the fixed cardiac output. If the aortic valve area was
<1.5cm2 it will have increased complications reported by a study
conducted by Siu 2001. Women with valve gradient exceeding 100mmHg
appear to be at increased risk. Maternal mortality rate was 8% described by
Hameed and co-workers. If symptomatic  bed rest, limitation of physical
activity and control of infection are suggested. Balloon valvotomy is
restricted because of grave complications like stroke, aortic rupture, aortic
regurgitation and death described by Carabello and Reich 200430,
Crawfoard 1997. In rare cases it may be done - Angel and co-workers
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1988, Lao and associates 1993, Datt 201031. Patient should be hydrated
sufficiently to prevent decrease in systemic vascular resistance. During
delivery, narcotic epidural analgesia is best as it avoids dangerous
hypotension a study conducted by Easterling and co-workers 198832. Slow
administration of dilute local anaesthesia was described by Camann and
Thornhill 1999, Xia and co-worker 200633. Tzemos and associate 200934
reported late cardiac events.
PULMONIC STENOSIS
It is usually congenital may be related with TOF or Noonan
syndrome pregnancy precipitate right side cardiac failure or atrial
arrhythmias described by Siv and Colman 2001. Cardiac complications
were infrequent during pregnancy described by a study conducted by
Drenthen 200635. If symptoms increased a balloon angioplasty was
necessary during pregnancy described by Siu 2001a36, Maxwell 201026.
MITRAL INSUFFICIENCY
Trivial mitral insufficiency is present in most normal patient by
Maxwell 201026. Mitral valve vegetation-Libman Sacs endocarditis are
common in patients with anti-phospholipid antibody described by Roldan
199637, Shroff 201238 Chronic mitral insufficient has a number of causes
which includes rheumatic fever, mitral valve prolapse ,etc. It is well
tolerated during pregnancy.
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AORTIC INSUFFICIENCY
It is caused by rheumatic fever, connective tissue abnormalities and
congenital with marfan syndrome. The aortic root may dilate resulting in
aortic insufficiency which may also develop with bacterial endocarditis.
Aortic and mitral insufficiency have been related to appetite suppressants
like fenfluramine and ergot derived dopamine agonist like cabergoline
described by Gardin 200039, Schade 200740, Zanettini 200741. It is well
tolerated during pregnancy.
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CONGENITAL HEART DISEASE
Cardiac Lesion
Congenital Heart Disease in Fetus (%)
Previous sibling
Affected
Father Affected
Mother
Affected
Marfan
syndrome
Not stated 50 50
Aortic stenosis 2 3 15-18
Pulmonary
stenosis
2 2 6-7
Ventricular
septal defect
3 2 10-16
Atrial septal
defect
2.5 1.5 5-11
Patent ductus
arteriosus
3 2.5 4
Coarctation of
the aorta
Not stated Not stated 14
Fallot tetralogy 2.5 1.2 2-3
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Risks For Fetal Heart Lesionrelalated To Affected Family Members
The incidence in US is 8 / 1000 live birth, nearly one million adults
in that country described by Bashore 200742. Patients admitted for delivery
with congenital heart disease was 71.6 per 1,00,000 deliveries reported by
a study conducted by Optotowsky 201243. Arrythmias was the most
common and the mortality rate was nearly 1.5 per 1000 described by
Thompson and associates 201444.
Atrial septal defect:
One fourth of adults have a patent foramen ovale described by Kizer
200545. Ostium secundumtype defect is more common in nearly 70% of
cases. Pregnancy is well tolerated unless pulmonary hypertension develops
but this is uncommon described by Maxwell 201026 and  Zuber 199946.
Aliago 200347 described risk of endocarditis was insignificant. Paradoxical
embolism is possible and may cause embolic stroke described by Erkut and
co-workers 200648. In asympomatic patients, prophylaxis for septal defect
is observation and low dose aspirin described by Kizer 200545 and Maxwell
201025.Head and Thorne 200549 suggested compression stockings &
prophylactic heparin for a pregnant mother with ASD & concurrent
immobility.
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Ventricular septal defect:
These lesions usually close during paediatric period in 90%. If the
defect is <1.25 cm, pulmonary hypertension and cardiac failuredonot
develop. If the defect size is larger than aortic valve orifice, symptoms
rapidly develop. Patients with unrepaired large defects develop left
ventricular failure& pulmonary hypertension and increased incidence of
bacterial endocarditis described by Brickner 200050, Maxwell 2010. So IE
prophylaxis is often recommended in large unrepaired defects.
Atrioventricular septaldefect:
It accounts for 3% of all congenital heart disease charecterised by a
common ovoid AV junction associated with aneuploidy, Eisenmenger
syndrome. Compared with simple septal defect complications are more
frequent during pregnancy A Study conducted by Drenthen2005b51
concluded worsening of NYHA, arrhythmias and cardiac failure.
Patent dcutus arteriosus:
Functional closure of ductus from vasoconstriction occurs shortly
after term birth hypothesis described by Akintunde 201152. Most of the
lesions are repaired in paediatric period. In unrepaired patients mortality is
high after 50 years was described by Brickner 200050. Unrepaired ductus
during pregnancy will develop pulmonary hypertension, cardiac failure &
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cyanosis if, systemic BP falls & leads to shunt reversal of blood from
pulmonary artery into aorta described by Maxwell 2010. A sudden
decrease in blood pressure during labour due to conduction analgesia or
bleeding may result in total collapse therefore hypotension should be
avoided.
Cyanotic Heart disease:
Most commonly encountered lesion in pregnancy is Fallot tetralogy
described by Maxwell 2010. It is characterised by large ventricular septal
defect, pulmonary stenosis, right ventricular hypertrophy and an over
riding of aorta. Women who have undergone repair and who do not have
recurrence of cyanosis tolerate pregnancy well. A study conducted by Balci
201153 and Kamiya 201254 described surgically corrected TOF well
tolerated pregnancy and no maternal death.  Oosterhof & associates 200655
described that pregnancy did not adversely affect graft function.
Single functional ventricle:
Fenistin 201256evaluated the treatment for patients with hypoplastic
left heart syndrome. Patients undergone a Fontan repair are at high risk of
atrial arrhythmias and cardiac failures described by Nitsche200959. Hoare
2001 reported no maternal death out of four post Fontan repaired patients.
High complication rates were described by Jain and worker 201158.
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Ebstein Anomaly:
Malpositioned malformed tricuspid valve right ventricular failure
and cyanosis are common during pregnancy. In the absence of cyanosis,
patients tolerate pregnancy well.
Eisenmenger Syndrome:
The most common lesions are ASD VSD or PDA. Patients are
asymptomatic for years but pulmonary hypertension becomes severe to
cause right to left shunt described by Makaryus200659, Maxwell 2010.
Maternal and perinatal mortality – nearly 50% reported by
Gleicher197960.Weies and co-worker 1998 reported 36% maternal
mortality rate. Wang 201161reported one maternal death among 13 mothers
and five perinatal deaths in a study.
Pulmonary Hypertension:
Normal resting pulmonary artery pressure is 12-16 mm Hg. A study
conducted by Clark and colleagues 1989 pulmonary vascular resistance in
late pregnancy was 34% less than non-pregnant. PHT is a haemodynamic
observation not a diagnosis where mean pulmonary pressure is more than
25 mm Hg. WHO classification adopted by ACC EAHA Mclauchlin
200462.
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One third of scleroderma have – PHT and 10% SLE have PHT
reported by Rich 200563. Sickle cell disease and thyrotoxicosis patients
have PHT but it is reversible with treatment – Cunnigham2004. Boggese &
colleague 199564described interstitial and restrictive lung disease have
varying degree of PHT. Patient with cirrhosis and portal HT have varying
degree of PHT and has been reported by Sigel 200765,cystic fibrosis
patients have PHT reported by Eden &co-workers 2000 pulmonary artery
pressure were over diagnosed by echo in 1/3 of cases reported by Penning
200166.Idiopathic PHT 3 years survival -60% Collagen vascular disease
causing PHT - only 35% reported by MC Laughlin 2004. Preconception
counselling is essential as highlighted by Easterling199967.
A study conducted by Curry 201268 and Weiss 199869reportedthe
mortality rate was nearly 30%. Bedard and associates 200970reported that
mortality statistics improved from 38% in 1996 to 25% in 2007.Pregnancy
is contraindicated with severe disease 80% death were during the first
month of puerperium.
Rest, oxygen, diuretics, vasodilators are standard treatments. Hsu
201171, Larson201072 recommended anticoagulation, Badalian200073,
Easterling1999,Garabedian201074 recommended I.V pulmonary artery
vasodilators. Humbert 200475, Roeleveld 200476recommended parenteral
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prostacyclin analogues. Lane201177 recommended inhaled nitric oxide is
useful for acute cardiopulmonary decompensation.
Parneix 200978 described low dose spinal or epidural analgesia for
LSCS, Weiss2000 & Lam 200179 described inhaled nitric oxide or iloprost.
Peripartum cardiomyopathy:
It is like all other forms of dilated cardiomyopathy except for its
distinctive relationship with pregnancy described by Pyatt201180. Pearson
200081 established the diagnostics criteria After thorough search and
excluding the underlying cause for heart failure, idiopathic cardiomyopathy
may be considered which is described by Born and Bettelet 1998, Hibhaw
and associates 1999; various aetiologies like viral, abnormal immune
response , haemodynamic changes due to pregnancy, hormonal
interactions, malnutrition, inflammations, oxidative stress during late
pregnancy were described by Elkayam201182, Hilfiker- Kleiner200783,
Sliwa 201084, Patten 201285.Hypertension coexisting with peripartum
cardiomyopathy, is described by Cunningham 201286, Fong 201487,
Gunderson 201188 and they postulate peripartum cardiomyopathy to be a
vascular disease. Bultmen 200589and co-workers studied endomyocardial
biopsy specimen and reported evidence of myocarditis to be present due to
genomic materials of parvovirus-19. Prevalence of peripartum
cardiomyopathy is 1 in 3200 birth was described by Mielnieczuk 200690.
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Two other studies conducted by Gunderson 2011, Harper 201291 showed
the prevalance was lin 2000 and lin 2800 respectively. In earlier study by
Cunningham 198692 shows 1 in 15,000.So the prevalence was increased.
One year maternal mortality rate is 2-15% reported by Harper 2012, but in
those with persistence cardiac failure the maternal mortality   was 85 %
over 5 years- Moioli 201093. In India, Mandal 201194 conducted a study
and reported the outcome of Peripartum cardiomyopathy -5 out of 36 was
died, another follow up study by Haiti, Fetl and co-worker 2009 shows
only 28% of these patients recovered. With a mean follow up of 39 months
De Souza and co-worker 200195 compared that 18% patients had died from
end stage cardiac failure.
Mitral valve prolapse:
A pathological connective tissue disorder – termed myxomatous
degeneration  of the valve leaflet annulus and chordae tendinae. Mitral
insufficiency may develop. Most of them are asymptomatic,   few of them
have symptoms like anxiety, palpitation , atypical chest pain, dysponea on
exertion& syncope hypothesized by Guy 201296. These patients have a
excellent pregnancy outcome - described by Lesniak-Sobelge 200497,
Rayburn 198798. In Taiwan, a study conducted by Chen 201199 reported
preterm birth rate was 1.2 times higher. Beta blockers are prescribed to
27
symptomatic patients according to ACOG 2011a& guidelines - is IE
Prophylaxis not indicated in MVP patients .
Diseases of the Aorta -:
Marfan syndrome & coarctation are two aortic diseases with
increased risk for aortic dissection,  50% of cases are related to pregnancy
hypothesized  by O’ Gara 2004100. Other causes are bicuspid aortic valve,
Turner & Noonan syndrome. The differential diagnosis for it are
myocardial infarction, pulmonary embolism, pneumothorax, aortic valve
rupture , placental abruption and uterine rupture was described by Lang
1991101. Pepin102&collegues described a high rate of aortic dissection in
Ehlers danlos syndrome.
Marfan  syndrome :
No racial predilection  described by Ammash 2008103. In a study by
Rossiter 1995104 out of 21patients, 2 patients had dissection one died
during puerperium from graft infection.  Rahman & coworekrs 2003103
hypothesized that no maternal death among 14 pregnant mothers. Aortic
dilatation reaches  5 to 6 cm elective surgery recommended before
pregnancy described by Gott 1999106 William 2002107. Simpson
20126reportedprophylactic B blockers reduces the haemodynamic stress
and slows the dilatation. Vaginal delivery - with aortic root dilatation was
4 cm to  5 cm or greater - elective LSCS and replacement of the proximal
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aorta with prosthetic graft during puerperium is hypothesized by Simpson
2012, but the surgery  is associated with fetal hypoxic ischemic cerebral
damage Mul 1998108 Seeburger 2007109. According to Goo 2011, Haas
2011, Papatsonis 2009110type A dissection was repaired favourably at the
time of Cesarean delivery. According to Meijboom 2006111,15% are
preterm deliveries.
Aortic coarctation:
Rare lesion - associated by abnormalities of large arteries. 25% have
bicuspid aortic valve, 10% have cerebral artery aneurysms. Others are
PDA, septal defects & Turner syndrome. Typical finding is hypertension in
upper limbs and normal pressure in lower limb. Coarctation is diagnosed
by MRI described by Dizon – Towson 1995112,sherer 2002113 zwiers
2006114. Beauchesue co-worker 2001115 described the outcome of 188
pregnancies. A study conducted by Krieger &colleagues 2011116 nearly 700
cases, 3 to 4 fold increase in  HT, 5% adverse cardio vascular outcome,
41% underwent LSCS
Infective endocarditis:
Bacterial infection involves cardiac endothelium and usually end in
valvular vegetations. The risk factors are CHD, IV drug abuse,
degenerative valve disease& intra cardiac devices - described by Karchmer
2012117. Staphylococcus aureus is the predominant organism in drug
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abusers& catheter related infections. Cox 1988118, Deger1992119 described
patients with antepartum endocarditis with Neisseria sicca and N.mucosa,
the latter  causing maternal death .Beta haemolytic streptococcus infection
causes endocarditis have been described by Kangavari 2000120.E coli cause
endocarditis following LSCS was described by Kulas 2006121. The illness
is flu like  described by karchmer 2012  diagnosed  by Duke’s criteria
( Hoen 2013 , Pierce 2012) patients are treated according to microbial
sensitivity was described by Darouiche 2004122, Karchmer 2012). Cox
1988 described an incidence of 1 in 16,000 Cox1989 , Seaworth 1986123
cited maternal mortality rate of 25 to 35%
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IE PROPHYLAXIS:
American College of Obstetricians and Gynaecologists (ACOG)
(2011a):
Standard (IV) : Ampicillin 2 g or cefazolin or ceftriaxone 1 g
Penicillin-allergic (IV) : Cefazolin or ceftriaxone 1g or Clindamycin
600mg
Oral : Amoxicillin 2g.
American Heart Association (Wilson, 2007)
Standard : Ampicillin 2g IV or IM or amoxicillin 2g (Oral)
Penicillin-allergic : Clarithromycin or azithromycin 500mg (Oral),
Cephalexin 500mg (Oral), Clindamycin 600 mg
(Oral), Intravenous, Intramuscular, or cefazolin
or ceftriaxone 1g intravenous or intramuscular.
Heart failure:
Women who develop cardiac failure almost always have obstetrical
complication like preeclampsia haemorrhage, Anaemia infection and
sepsis, chronic HT and obesity. Jess up 2003124described first sign in
basilar rales associated with nocturnal cough. Clinical findings may include
haemoptysis, oedema, tachycardia and rarely cardiac dyspnea is universal.
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Orthopnoea palpitations& chest pain – substernal are described by hibbard
1999. Ejection fraction <0.45%fractional shortening <30% end diastolic
dimension >2.7 cm/m2 were managed with diuretics and anti HT &
prophylactic heparin. Left ventricular outflow device are employed –
described by La Rue 2011125, sime 2011. Extracorporeal membrane
oxygenation reported to be life saving – smith 2009126.
Surgically corrected heart disease:
Most clinically significant CHD are repaired during child hood,
those frequently not diagnosed until adulthood include ASD, PS, Bicuspid
aortic valve & coarctation of aorta  described by brickner co-worker 2000
Valve replacement:
Porcine type valves are much safer during pregnancy. However
valvular dysfunction with cardiac failure is common and these are not as
durable as mechanical one, valve replacement longevity averages 10-15
years. Cleuzious and co-workers 2010127 reported shunt pregnancy does
not accelerate the risk for replacement anticoagulation with heparin is less
risky for the foetus but the risk of maternal thromboembolic
complications are more described by MC Lintock 2011128. Chen and
coworkers reported warfarin during pregnancy has good pregnancy
outcome but the embryopathy rate was6.4 % chen 2000 Itur be alessio
1986129.described anticoagulation for mechanical valve using low dose
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UFH is inadequate & maternal mortality rate was increased Leyh
2002129.,2003 Rowan 2001130described both UFH & LMWH are associated
with valvular thrombosis  anticoagulation with warfarin or heparin may
be restarted 6 years following vaginal delivery and 6-12 hrs following
LSCS recommended by AGOG 2011 b because they do not accumalate in
breast milk so that they do not induce an anticoagulant effects in the
infant ACOG 2011B.
Cardiac surgery during  pregnancy:
Sutton and co-workers 2005131 described maternal mortality with
cardiopulmonary bypass are between 1.5 &2.5 % total mortality rate are
nearly 20% John-2011132and co-workers hypothesized that pregnant
mothers who underwent cardiothoracic surgery the urgency required
cardiopulmonary bypass Chandrasekar  and associates 2009133
recommended surgery done electively when possible pump flow rate
maintained 7.25 L/ mt/mt2 normothermic perfusion pressure 770mmHg
and haematocrit>28% Pavankumar 1988134 conducted a study and reported
tight mitral stenosis require intervention during pregnancy which was
previously treated by closed mitral valvotomy percutaneous transcatheter
balloon dilatation is largely done described by Fawzy 2007135&Rahimtoole
2006136and Est eves co-workers 2006137.
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Pregnancy after heart transplantation:
Lowenstein & co-workers 1988 138was reported successful
pregnancy after heart transplantation key 1989 and kim 1996139
hypothesized transplanted heart responds normally to haemodynamic
change during pregnancy. Dashe 1998140 described complication are
common. Arementi 2002 outcome of 37 heart recipient reported that 50%
developed HT , 22 % one rejection, usually delivered by LSCS at 37-38
was >5% infants are live born. Estensen & co-workers 2011 reported that
there was no maternal death by a study from sandinevia. Ethical
consideration and counselling were outlined by Rose 2016140.
Contraception:
This is much more important because they should limit their family
size and complete their families  before there is serious cardiac
deterioration.
Oral contraceptives carry the risk of hypercoagulability,
thromboembolism, hypertension and hyperlipidemia IUCD carry the risk
of vaso vagal syncope due to pain during the time of insertion and
infection. It is prevented by smaller size Copper T and prophylactic
antibiotics- brebeer 1975.Barrier methods of contraception are safe but
have a low efficacy. These and low dose oral pills are preferable to IUCD.
Soon after completion of family, sterilization should be advised.
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MATERIALS AND METHODS
The study of maternal and perinatal outcome in heart disease
complicating pregnancy was carried out in Tirunelveli medical college .
This was done during a period of 14 months starting from June 2015 to
July 2016 and total of 107 mothers with heart disease complicating
pregnancy were studied.
Methodology:
1. Correct and careful history taking including H/O rheumatic fever,
H/O failure, pulmonary oedema etc., during antecedent pregnancies
details of recognised heart disease, details of treatment undergone
and H/O any surgery done for heart disease.
2. A through clinical examination.
3. Clinical diagnosis was made & the pregnant mothers were
investigated.
ECG and echocardiogram were done for all the mothers.
CBC,RFT,LFT, routine urine analysis were done for all patients.
TFT and coagulation profile were done for indicated cases. Pregnant
mothers were classified according to NYHA classification and
managed accordingly.
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Inclusion Criteria:
All pregnant mothers with various heart disease.
Exclusion Criteria:
All pregnant women without any heart disease but having signs  and
symptoms suggestive of heart disease were evaluated and newly diagnosed
heart disease patients were included in the study and mothers suny heart
disease were excluded.
Routine management: ANC
Patients with diagnosed heart disease were first admitted for correct
evaluation & clinical grading. The patients in functional class I &II  were
discharged and advised to attend the OPD regularly. The frequency of
antenatal visits were determined by their cardiac status. They were
suggested to take sufficient rest to avoid sternous work, stress and  take salt
restricted diet. Any infection if present was treated vigorously and were
advised to avoid contact with persons having respiratory infections
including common cold & to report at once if there was any evidence for
infection.
Patients were in functional class I &II were admitted at 32-34 weeks
, functional class III  and IV were admitted immediately  .Patients with
evidence of decompensated heart were admitted in ICU of labour ward.
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Provided strict bed rest, Oxygen and the treatment as advised by
cardiologist.
Labour:
In general, vaginal delivery is a better option so the main principle in
obstetric management was to wait for the spontaneous onset of labour.
Patients were in semi recumbent position with lateral tilt. They were
sedated in the first stage IV line was maintained. Prophylactic antibiotics
were given routinely. If the patients were on drugs, the drugs were
continued or else started as per cardiologist advice. Pulse rate, respiratory
rate blood pressure and foetal heart rate were monitored. Instruments were
used to cut short the second stage. Episiotomy and perineal lacerations
were sutured under local anaesthesia. LSCS was done for obstetric
indications only under epidural anaesthesia. After delivery the first 12-24
hours was carefully monitored for signs of failure & post partum
hemorrhage and they were kept in intensive care unit for 48 hrs and were
kept in postnatal ward for 14 days.
Babies were followed up by the paediatrician. Breast feeding was
allowed except in grade IV failure because it increases the cardiac output.
Patients were discharged after getting fitness for discharge from
cardiologist. Patients were advised about contraception and postnatal
follow up was given.
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OBSERVATION AND RESULTS
The present study was conducted in Tirunelveli Medical College,
Obstetrics and gynaecology department for a period of 14 months from
June 2015-July 2016 among the antenatal cases with heart disease. During
the study period total number of pregnant patients with heart disease were
107. Out of these 107 patients, 98 patients delivered and 4 underwent
MTP, 5 patients were delivered outside and referred here for further
management.
Total number of delivers in Tirunelveli Medical College Hospital
during the study period was 7830 out of which 98 deliveries were with
heart disease.
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TABLE-1: INCIDENCE OF HEART DISEASE
Sl.
No
Total No of
delivery
Delivered
mothers with
Heart disease
Delivered
mothers
with
normal
CVS
Incidence of
Heart disease
1 7830 98 7732 1.25%
FIG: 1 INCIDENCE OF HEART DISEASE
78
30
98
77
32
Total No of delivery Heart diseased delivery Normal Mothers Delivery
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TABLE-2: DISTRIBUTION OF HEART DISEASE AMONG THE
TOTAL DELIVERIES DURING  STUDY PERIOD
A total  of 107 cardiac mothers were admitted. They were classified
according to the nature of their disease. Among the 107 patients, CHD was
35 (32.7%), RHD was 53 (49.5 %) and others were 19 (17.8%).
Sl. No Category of Heartdisease
No. and % of Heart
disease deliveries
Heart diseases
deliveries rate /
1000 (n=7830)Frequency %
1 CHD 35 32.7 4.5
2 RHD 53 49.5 6.8
3 OTHERS 19 17.8 2.4
Total 107 100.0 13.7
The incidence of CHD, RHD and others were 0.4, 0.6  and 0.2
respectively.
FIG: 2: DISTRIBUTION OF HEART DISEASE AMONG THE
TOTAL DELIVERIES DURING  STUDY PERIOD
33%
49%
18%
CHD RHD OTHERS
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TABLE-3:DISTRIBUTION OF HEART DISEASE ACCORDING TO
PURPOSE OF ADMISSION
Sl. No Purpose of
admission
Total No.of.cases Percentage
1 Delivery 98 91.58%
2 MTP 4 3.73%
3 Delivered outside 5 4.67%
FIG 3: DISTRIBUTION OF HEART DISEASE ACCORDING TO
PURPOSE OF ADMISSION
91%
4% 5%
Delivery
MTP
Others
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TABLE-4 : DISTRIBUTION OF MOTHERS ACCORDING TO
THEIR SOCIO ECONOMICS Status
Sl
No
Socio Economics
Status Frequency % χ
2 df Sig
1 II 3 2.8
49.523 3 P<0.001
2 III 39 36.4
3 IV 49 45.8
4 V 16 15.0
Total 107 100.0
Table  4 shows, 45.8% cases  belong to class IV, 15% patients belong to
classV and 36.4% patients belong to class III.
FIG: 4: DISTRIBUTION OF MOTHERS ACCORDING TO THEIR
SOCIO ECONOMICS STATUS
3%
36%
46%
15%
II
III
IV
V
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TABLE-5: ASSOCIATION BETWEEN ANTENATAL
REGISTRATION WITH HEART DISEASES:
Parity
CHD RHD Others Total χ2 df SigN
o
% No % N
o
% No %
Booke
d 34 97.1 48
90.
6 19
100.
0
10
1 94.4
3.09
5 2
P>0.0
5
Un
booke
d
1 2.9 5 9.4 0
0.0
6 5.6
Total 35 100.0 53
49.
5 19
17.8 10
7
100.
0
FIG:5:ASSOCIATION BETWEEN THE  ANTENATAL
REGISTRATION WITH HEART DISEASES
Out of 107 patients, 101 were booked and 6  were unbooked. There
was no maternal or perinatal mortality among the unbooked cases.
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B OOKED UN  BOOKED
ASSOCIATION BETWEEN THE ANTENATAL
REGISTRATION WITH HEART DISEASES
CHD RHD Others
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TABLE-6: AGE WISE DISTRIBUTION OF HEART DISEASES IN
PERCENTAGE
Age
group
CHD RHD Others Total
Frequenc
y %
Frequenc
y %
Frequenc
y % Frequency %
<20 1 2.9 1 1.9 1 5.3 3 2.8
20-24 18 51.4 19 35.8 5 26.9 42 39.3
25-29 9 25.7 22 41.5 9 47.4 40 37.4
30-34 6 17.1 9 17.0 3 15.8 18 16.8
35-39 1 2.9 2 3.8 1 5.3 4 3.7
Total 35 100 53 100 19 100 107 100
Mean±SD 25.3±4.3 26.0±3.8 26.7±4.2 25.9±4.0
Signifi F= 0.717and P>0.05 Range  36-19=17
Majority of cases were in the age group 20-30 years.
FIG:6: AGE WISE DISTRIBUTION OF HEART DISEASES IN
PERCENTAGE
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TABLE-7: DISTRIBUTION OF CHD, RHD AND OTHER
MOTHERS ACCORDING TO THEIR PARITY
Parity CHD RHD Others Total χ2 df SigNo % No % No % No %
Primi 18 16.8 20 18.7 6 5.6 44 41.1
2.501 1 P>0.05Multi 17 15.9 33 30.8 13 12.1 63 58.9
Total 35 32.7 53 49.5 19 17.8 107 100.0
FIG 7: DISTRIBUTION OF CHD, RHD AND OTHER MOTHERS
ACCORDING TO THEIR PARITY
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Diagnosis of heart disease
The practice of taking  ECG and obtaining physician’s opinion for
all the antenatal mothers is now being followed in our hospital. Many
patients with MVPS with or without valvular dysfunction with
deterioration in their functional status are being diagnosed during
pregnancy.
TABLE-8 : TIME OF DIAGNOSIS OF HEART DISEASE:
Sl.No Time of diagnosis  of heart disease Percentage
1 Heart disease diagnosed  during
pregnancy
92.52%
2 Heart disease diagnosed  before
pregnancy
7.4%
FIG:8: TIME OF DIAGNOSIS OF HEART DISEASE:
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
100.00%
Heart disease99 (before pregnancy) 8 cases (during pregnancy)
46
TABLE-9: PERCENTAGE DISTRIBUTION OF CHD ACCORDING
TO THE SUB CLASSIFICATION CATEGORY:
Sl. No. CHD Type Frequency %
1 ASD 13 37.1
2 ASD/Mild TR 1 2.9
3 ASD/VSD 1 2.9
4 bicuspid AV 2 5.7
5 OS ASD with (M) PS/PR 1 2.9
6 OS-ASD 2 5.7
7 PDA 4 11.4
8 PS 1 2.9
9 TA with VSD single ventricle 1 2.9
10 VSD 8 22.9
11 VSD -PS 1 2.9
Total 35 100.0
FIG:9:  DISTRIBUTION OF CHD ACCORDING TO THE SUB
CLASSIFICATION CATEGORY
37%
3%3%5%3%6%
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3%3%
23%
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OS ASD with (M) PS/PR
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PS
TA with VSD single ventricle
VSD
VSD -PS
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TABLE-10:  DISTRIBUTION OF RHD ACCORDING TO THE SUB
CLASSIFICATION CATEGORY
Sl. No. RHD Type Frequency %
1 MR AR 4 7.5
2 AS AR 2 3.8
3 MS 10 18.9
4 MS MR 17 32.1
5 MS MR AR 3 5.7
6 MS severe, mild MR 2 3.8
7 severe   MR 1 1.9
8 (S) MS MILD AR TR PHT 1 1.9
9 Mild AS Mild AR 1 1.9
10 MS (S)/ MR/TR/PHT 1 1.9
11 MS(S) MR /PHT 1 1.9
12 MS(S) M(MR) PHT 1 1.9
13 Severe MS Mild AR / Mild PHT 1 1.9
14 TR 2 3.8
15 MR 4 7.5
16 MR TR 1 1.9
17 Trivial TR MR 1 1.9
Total 53 100.0
FIG10: DISTRIBUTION OF RHD ACCORDING TO THE SUB
CLASSIFICATION
7.5
3.8
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32
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TABLE-11:  DISTRIBUTION OF OTHER HEART DISEASES
ACCORDING TO THE SUB CLASSIFICATION CATEGORY
Sl.
No. Other heart diseases Type Frequency %
1 Ebstein anomaly 1 5.3
2 MVPS/TR 1 5.3
3 MVPS / AR 1 5.3
4 MVPS MR TR 1 5.3
5 MVPS with MR 6 31.6
6 MVPS with TR 1 5.3
7 MVPS with trival MR 1 5.3
8 MVPS-PR 1 5.3
9 MVPS/AML 1 5.3
10 PPCM 5 26.3
Total 19 100.0
FIG: 11: DISTRIBUTION OF OTHER HEART DISEASES
ACCORDING TO THE SUB CLASSIFICATION CATEGORY
5.3 5.3 5.3 5.3
31
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TABLE-12 : NYHA STATUS CLASSIFICATION OF CARDIAC
SUBJECTS:
Parit
y
CHD RHD Others Total
χ2 df SigN
o
% No % N
o
% No %
Good 34 97.1 45 84.9 15 78.9 94 87.9
4.67
3 2
P>0.0
5Bad 1 2.9 8 15.1 4
21.
1 13 12.1
Total 35 100.0 53
100.
0 19
17.
8
10
7
100.
0
Majority of  patients belong to NYHA class I and II.
Good prognosis – NYHA class I and II
Bad prognosis - NYHA Class III and IV
FIG:12 NYHA STATUS CLASSIFICATION OF CARDIAC
SUBJECTS:
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TABLE:13 :PREGNANCY OUTCOME IN PATIENTS   ADMITTED FOR
DELIVERY
Pregnancy Outcome Number of Case Percentage
Vaginal delivery 70 71.42
LSCS 27 27.55
Died un delivered 1 1.02
This table shows majority of patients (71.42 % ) were delivered by normal vaginal
delivery.
FIG: 13 :PREGNANCY OUTCOME IN PATIENTS   ADMITTED FOR
DELIVERY
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TABLE:14: DISTRIBUTION OF NORMAL AND INSTRUMENTAL  VAGINAL
DELIVERY
S.No. Type of delivery No. Cases %
1. Labour natural 40 57.14
2. Outlet forceps 19 27.14
3. Vacuum extraction 9 12.85
4. Assisted Breech
Delivery
2 2.85
FIG:14: DISTRIBUTION OF NORMAL AND INSTRUMENTAL  VAGINAL
DELIVERY
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TABLE: 15: DISTRIBUTION OF LABOUR NATURAL
S.NO. Type of Delivery Number of  Cases %
1. Labour Natural 17 42.5
2. LN with episiotomy 23 57.5
FIG:15: DISTRIBUTION OF LABOUR NATURAL
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TABLE: 16: DISTRIBUTION OF LSCS
S. No. Type of LSCS Cases %
1. Emergency primary LSCS 14 51.85
2. Emergency repeat LSCS 2 7.40
3. Elective primary LSCS 2 7.40
4. Elective repeat LSCS 9 32.33
FIG: 16: DISTRIBUTION OF LSCS
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TABLE 17: INDICATION OF PRIMARY EMERGENCY LOWER
SEGMENT CAESAREAN SECTION
Indication Number of cases Percentage
Cephalopelvic  Disproportion 4 28.57%
Premature  rupture of membrane 2 14.28%
Breech 3 21.42%
Foetal distress 5 35.71%
FIG 17 : INDICATION OF PRIMARY EMERGENCY LOWER SEGMENT
CAESAREAN SECTION
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TABLE 18: INDICATION OF EMERGENCY REPEAT LOWER SEGMENT
CAESAREAN SECTION
Sl.
No
Indication Number
of cases
Percentage
1 Previous LSCS with CPDI 1 50%
2 Previous LSCS with PROM 1 50%
FIG: 18:INDICATION OF EMERGENCY REPEAT LOWER SEGMENT
CAESAREAN SECTION
Previous LSCS with
CPD minor
50%
Previous LSCS with
PROM
50%
Percentage
Previous LSCS with CPD minor
Previous LSCS with PROM
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TABLE 19: INDICATION OF PRIMARY ELECTIVE LOWER
SEGMENT CAESAREAN SECTION
Sl.
No
Indication Number of
cases
Percentage
1 CPD Major 1 50%
2 Flexed Breech 1 50%
FIG:19: INDICATION OF PRIMARY ELECTIVE LOWER SEGMENT
CAESAREAN SECTION
CPD Major
50%
Flexed Breath
50% CPD Major
Flexed Breath
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TABLE: 20: INDICATION OF ELECTIVE REPEAT LOWER
SEGMENT CAESAREAN SECTION
Sl.
No
Indication Number of
cases
Percentage
1 Previous LSCS with CPD 8 88.88%
2 Previous LSCS with Breech 1 11.11%
FIG: 20: INDICATION OF ELECTIVE REPEAT LOWER
SEGMENT CAESAREAN SECTION
Previous LSCS with
CPD
89%
Previous LSCS with
Breech
11%
Previous LSCS with CPD
Previous LSCS with Breech
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TABLE 21: DISTRIBUTION OF COMPLICATION OF HEART
DISEASE DEVELOPED DURING PREGNANCY
S.NO. Complication Number of
cases
Percentage
1. Severe Pulmonary
Hypertension
3 33.33
2. Acute pulmonary oedema 3 33.33
3. Congestive cardiac failure 1 11.11
4. Embolic manifestation 2 22.22
FIG: 21 DISTRIBUTION OF COMPLICATION OF HEART DISEASE
DEVELOPED DURING PREGNANCY
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TABLE 22 : DISTRIBUTION OF RISK FACTORS ASSOCIATED
WITH THE CARDIAC DISEASE
S.No. Complication No. of
cases
%
1. Aanemia 13 34.21
2. Gestational hypertention 4 10.52
3. Gesational diabetes mellitus 9 7.89
4. Rh negative 10 26.31
5. Hypothyroid 4 10.25
6. Premature rupture of membrane 2 5.26
7. Preterm Premature rapture of membrane 1 2.63
8. UTI Urinary tract infection 1 2.63
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FIG: 22 DISTRIBUTION OF RISK FACTORS ASSOCIATED WITH
THE CARDIAC DISEASE
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TABLE:23: DISTRIBUTION OF SURGICALLY CORRECTED HEART
DISEASE
S.No. Surgery No. of cases %
1. Closed Mitral commisurotomy 4 14.81
2. Baloon valvoplasty 2 7.4
3. ASD Closure 3 11.11
4. VSD closure 5 18.51
5. PDA ligation 3 11.11
6. Mitral  valve replacement 6 22.22
7. As with AR –Sub Aortic excision 1 3.7
8. TOF Corrected 1 3.7
9. MS- MR Annuloplasty 1 3.7
FIG:23: DISTRIBUTION OF SURGICALLY CORRECTED HEART DISEASE
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TABLE-24: BIRTH WEIGHT OF BABIES ACCORDING TO THE
TYPE OF HEART DISEASES
Sl.
No
Type of
Heart
Disease
n Mean SD “F” df Significance
1 CHD 34 2.6 0.5
0.286 2, 96 P>0.052 RHD 46 2.6 0.43 Others 19 2.7 0.5
Total 99 2.6 0.4
FIG: 24: BIRTH WEIGHT OF BABIES ACCORDING TO THE
TYPE OF HEART DISEASES
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TABLE-25: ASSOCIATION BETWEEN HEART DISEASES AND
MATURITY OF THE BABY
Heart
Disease χ2 df SigPre term Term Total
No % No % No %
CHD 3 3.0 31 31.3 34 34.3
0.361 2 P>0.05RHD 6 6.1 40 40.4 46 46.5Others 2 2.0 17 17.2 19 19.2
Total 11 11.1 88 88.9 99 100.0
FIG: 25: ASSOCIATION BETWEEN HEART DISEASES AND
MATURITY OF THE BABY
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TABLE 26: DISTRIBUTION OF PERINATAL MORBIDITY
S.No. Reason for Admission No cases %
1. Respiratory  distress syndrome 4 26.66
2. IUGR 1 6.66
3. MAS- Meconium aspiration syndrome 2 13.33
4. SGA- Small for gestational age 4 26.66
5. For maternal complication 4 26.66
Out of the 15 admission 1 baby expired in the early neonatal period
due to RDS
FIG: 26: DISTRIBUTION OF PERINATAL MORBIDITY
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TABLE:27 DISTRIBUTION OF CASES ACCORDING TO
ACCEPTANCE OF CONTRACEPTIVE METHODS
S.NO. Contracetptive method No. cases %
1. Copper T 23 23.46
2. Puerperal sterilisation 7 7.14
3. LSCS with Sterilisation 1 1.02
4. Barrier Methods 66 68.04
FIG:27 DISTRIBUTION OF CASES ACCORDING TO
ACCEPTANCE OF CONTRACEPTIVE METHODS
4 patients were admitted for MTP. Out of 4 patients, one patient
died, 2 patients had copper T insertion, one underwent tubectomy. All
MTP were done by manual vacuum aspiration by MVA Syringe.
ECHO was done for all cardiac patients .
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TABLE  28: DISTRIBUTION OF CASES ACCORDING TO
EJECTION FRACTION
E.F. Category CHD % RHD % Other %
>60% Normal 24 22.42 25 23.36 14 13.08
40-60 Mild 11 10.28 22 20.56 2 1.86
30-40 Moderate 0 0 3 2.80 1 0.93
<30 Severe 0 0 3 2.80 2 1.86
Total 35 53 19
FIG 28: DISTRIBUTION OF CASES ACCORDING TO  EJECTION
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TABLE-29:CATEGORY OF EF IN RELATION TO THE TYPES OF
HEART DISEASE
Category
CHD RHD Others Total
χ2 df SigNo % No % No % No %
Normal 24 68.6 25 47.2 14 73.7 63 58.9
2.018 1* P>0.05Abnormal 11 31.4 28 52.8 5 26.3 44 41.1
Total 35 100.0 53 100 19 100 107 100
The table associates normal and abnormality.There was
no statistically significant association between heart diseases (P>0.05).
FIG: 29: CATEGORY OF EF IN RELATION TO THE TYPES
OF HEART DISEASE
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TABLE-30 : PREGNANCIES WITH OR WITHOUT
CARDIOACTIVE DRUGS
Category
CHD RHD Others Total
χ2 Df Sig
No % No % No % No %
On drug 3 8.6 44 83.0 5 26.3 52 48.6
4.592 1* P<0.05Not on drug 32 91.4 9 17.0 14 73.7 55 51.4
Total 35 100 53 100 19 100 107 100
In the above table  the studied subjects had been classified according
to the drug administration. The patients  on drugs were 48.6% and not on
drug were 51.4%.
FIG 30: PREGNANCIES WITH OR WITHOUT
CARDIOACTIVE DRUGS
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TABLE:31: ASSOCIATION BETWEEN TYPE OF HEART
DISEASE AND MATERNAL MORTALITY
Heart
disease
Alive Died Total X2 df Sig
No % No % No %
CHD 35 32.7 0 0.0 35 32.7 4.480 2 P>0.05
RHD 47 43.9 6 5.5 53 49.5
Other 18 16.8 1 0.9 19 17.8
Total 100 93.5 7 6.5 107 100.0
FIG: 31: ASSOCIATION BETWEEN TYPE OF HEART DISEASE
AND MATERNAL MORTALITY
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DISCUSSION
The incidence of heart disease among pregnant women in the present
study was 1.25 % .Various study shows the incidence and it is compared
with our present study.
Mudaliar & menon - 0.97%
Deshmukh et al - 0.5%
Kamala sikdar - 0.5%
Chia - 0.7%
Deswiet & fidle - 0.5%
Present study - 1.25%
Socioeconomic status:
This has as an main place in the prognosis of patients with heart
disease. In the present study, 60% patients belonged to IV & V . Nafeesa
beebi et al reported that 92% of their patients belonged to class IV and V.
These mothers may gain less weight during antenatal period and
decreased antenatal care due to their low socio economic status.
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Antenatal care:
We have observed that nearly 5.6% of the patients were unbooked
and 94.4 patients were booked in TVMCH or nearby primary health
centres. There was no maternal and perinatal mortality among the
unbooked.
7.5% of our patients were undiagnosed prior to pregnancy, 92.5%
were diagnosed prior to pregnancy and underwent treatment even before
becoming pregnant and among these 80% of them were having regular
follow up care. 20% of the patients on irregular follow up care formed the
major part of patients who ultimately had poor outcome in the study.
Patients with complete and   regular antenatal check up generally had a
good prognosis.
Age and parity of the patients:
Chesley (1975) Mudaliar and Menon (1978) stated that aggravation
of rheumatic heart disease is due to the progressive nature of the lesion
with age rather then with  parity. In present study nearly 79.5% cases were
under the age of 30 years. Younger the patients better the prognosis In this
series also prognosis worsened with increasing maternal age. No grand
multigravida patient was in this study compared to the report by Dr. Lalitha
anantha Subramanian who had 20.5% grand multigravida. This shows the
awareness of patients about the risk of pregnancy in those with cardiac
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lesions. Motivation of these patients for sterilisation has brought down the
incidence in multiparous women.
Type of heart disease:
In older studies done by kamala sikdar 1980, mudaliar & menon
1972 incidence of rheumatic heart disease is 90-96% latest study is done
in western countries by Tan Deswein 1998 who reported that incidence of
rheumatic heart disease only 12%, chia 1998 reported that incidence
rheumatic  heart disease was 61.6% and congenital heart disease was 38.4.
Brickner and coworkers 2000 has  showed that better medical care together
with a number of newer surgical techniques enable more girls with
congenital heart disease to reach child bearing age.
In our study 49.5% of patients had rheumatic heart disease 32.7%
patients had congential heart disease while 17.8% patients had mitral
valve prolapsed, Ebstein anomaly and peripartum  cardiomyopathy. This
correlates with Brawn Wald 1984 report  which showed that rheumatic
disease of the heart is not more that 75% of pregnant cardiac patients. By
improving the standards of personal health and hygiene can lead to an
overall fall in the incidence of heart disease during pregnancy by 25-50%.
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Rheumatic heart disease:
In the study by szekely et al showed that dominant mitral stenosis in
90% mitral regurgitation 6.6% and aortic stenosis 1% and aortic
regurgitation 2.5%. Unlike szkely study, the present study showed only
20% had isolated mitral stenosis, isolated mitral regurgitation was seen  in
7.5% ,1.9% had aortic regurgitation with aortic stenosis Mitral stenosis
with regurgitation was seen in 32% and others had Multi valvular lesions.
The diagnosis of these lesions  is very important in the management of
these patients  during delivery because mitral stenosis should be managed
on the dry side in labor and aortic stenosis should be managed on the wet
side.
Congenital heart disease:
The incidence of various congenial heart disease is comparable with
the incidence of the congenital heart   disease in the general population. In
our study 37% had atrial septal defect and all the defects were of the
ostium secundum type 22.9% patients had ventricular septal defect  11.0%
patients had patent  ductus arteriosus 2.9% had pulmonic  stenosis 2.9%
had tetralogy of fallot .The maternal and perinatal outcome in these
patients  was influenced by the functional status of these patients according
to the NYHA classification. The foetomaternal  outcome was good.
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One case of tetralogy of fallot was acyanotic type, one case of
Ebstein’s anomaly but both had a good outcome without any
complications.
Mitral valve prolapse and other cardiac disease:
There was 5 patients of cardiomyopathy. Out of 5 patients of
peripartum  cardiomyopathy, there was one maternal death, one with
chronic hypertension one patient with Gestational hypertension and acute
pulmonary edema. There was no infant death.
Mitral valve prolapse is commonly seen in relation  to pregnancy. In
our study 12.14% of the pregnancy had mitral valve prolapse syndrome. In
many patients mitral valve prolapse  was diagnosed during the routine
check up done in the antenatal clinic and the patients  were totally
asymptomatic. Sometimes patients with this syndrome develop
complications. In our study 5.3% of patients who had mitral valve prolapse
had no regurgitation. 31.6% patients had mitral regurgitations,10.6% had
tricuspid regurgitation, 5.3% patients had both mitral and tricuspid
regurgitation, 5.3% had tricuspid regurgitation, 5.3% had aortic
regurgitation. MVPS with regurgitation had more risk for bacterial
endocarditis.
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Complications of heart disease during pregnancy:
Patients with rheumatic heart disease had more risk of developing
complications like cardiac failure, pulmonary oedema, systemic or
pulmonary embolism, infective endocarditis and cardiac failure.
In our study 38.3% patients had cardiac failure. Increased age,
anaemia, GHT and infection are the factors which increased the incidence
of cardiac failure.
Atrial fibrillation:
Szekely and smith have reported that atrial fibrillation increase the
risk of thromboembolism  and cardiac failure. Patients with mitral stenosis
and atrial fibrillation may develop pulmonary oedema. Atrial fibrillation
was developed in 11.11% patients in our study
Acute pulmonary oedema:
In rheumatic heart disease patients pulmonary oedma is the serious
complication. It has been the most important single cause of maternal
death. In our study 33.33% patients had pulmonary oedma. It shows that
severe mitral stenosis can lead to acute pulmonary oedma and maternal
death in pregnancy. Closed mitral commisurotomy  or balloon mitral
valvoplasty can be the life saving measure in these patients.
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Thromboembolic event:
In our study 22.22% patients had developed thromboembolic
manifestations. One patient P1L1, a booked and delivered outside by LSCS
developed fever and stroke and was referred to here as a case of infective
endocarditis with cerebral embolism. This patient had a history of mitral
valve replacement done on 2009. Here the patient was diagnosed as a case
of embolic stroke with infective endocarditis. CT brain showed ischemic
infarct of left corona radiata. Patients was shifted to IMCU for further
management. Patient died inspite of all treatment. . This emphasizes  the
importance of IE prophylaxis. Another patient was also a P1L1booked and
delivered outside and referred here as a case of CVT. She was diagnosed to
have mitral stenosis with mitral valve 0.9 cm2 and left atrial dilatation
and 2 mobile clots in left atrial appendage. CT Brain was taken and that
showed hypodense lesion in right capsuloganglionic  region. she was
treated by our cardiologist and neurophysician and then discharged after
15 days with good general conditionCoexisting aggravating factors:
Anaemia: In our study 34.21% had anemia ,13 cases of anemia  associated
with heart disease, 3 patients had  severe  anaemia and 10 patients had
moderate anemia. Patients with anemia are belonged to low socio
economic status. Anaemia was directly linked to preterm delivery, SGA
and cardiac failure. 2 patients had preterm delivery, two patients had small
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for gestational age baby and one patient with anaemia was admitted for
MTP. There was no maternal or perinatal morality.
Gestational Hypertension:
In our study 10.5% of patients had GHT. The association of pre-
eclampsia and eclampsia cases was Nil. Associated GHT make  the
perinatal outcome worse due to ulteroplacental insufficiency. It  also
makes the maternal outcome worse by producing pulmonary odema and
peripartum cardiomyopathy. But in our study there was no maternal and
perinatal mortality or morbidity.
Other complications:
3 patients had gestational diabetes 4 patients had hypothyroidism, 10
patients had  Rh negative blood group and one patient had urinary tract
infecion. There was no maternal or perinatal mortality  or morbidity.
Surgically treated patients:
In our study 4 patients had undergone CMC ,2 patients had
undergone balloon valvoplasty, 3 patients underwent ASD closure, 5
patients underwent VSD closure, 3 patients underwent PDA ligation, 6
patients underwent mitral valve replacement, one patients underwent
ASD and VSD closure, one patient of AS with AR underwent subaortic
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excision  , one patient underwent TOF correction and one patient MS with
MR underwent annuloplasty. All were done prior to pregnancy.
Purpose of Admission:
In our study 91.5% patients with heart disease were admitted for safe
confinement . Out of these 98 patients, one died undelivered, 3.7%
patients with heart disease were admitted for MTP .Out of these 4 patients,
one died after MVA due to severe pulmonary hypertension with multi
organ  failure. 4.67% of patients were delivered outside and got admitted
for further management out of these 5 patients, 2 patients died. One patient
died due to peripartum  cardiomyopathy – irreversible cardiogenic shock
and another one died due to cardio embolic stroke.
Mode of delivery:
In our study among the 98 patients admitted for safe confinement
.71.4% had vaginal delivery ,27.5% delivered by caesarean section ,1 died
undelivered. A study conducted by k. sidkar showed 90.7% were delivered
vaginally, 1.7% were delivered by caesarean section, 3.5% died
undelivered. In our study among the vaginal delivery 57.1% were labor
natural, 27.14% were outlet forceps 12.8% were vacuum extraction, 2.8%
were assisted breech delivery.  Caesarean section deliveries  were   done
mainly for obstetric indication. There were liberal use  of outlet forceps
and vaccum to cut short the second stage of labor.
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Perinatal outcome:
(Congenital anomaly incidence in various studies)
White more et al 1982 10%
Shime et al 1987 13%
Per off 1997 5-10%
Our study 2016 0%
In our study  11% babies were preterm, 99 % were term. There were no
congenital anomalies or congenital heart disease.
Perinatal mortality rate:
There were 2 intra uterine deaths, one was delivered at TVMCH,
another one was delivered at peripheral hospital. One preterm baby expired
due to respiratory distress syndrome.
Perinatal mortality in various studies
Beebi et al 1985 13.6%
Szekely snaith 1977 35%
Dipak babu et al 1995 5.4%
Out study 2016 1.02%
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There was a decline in the perinatal mortality and morbidity with
good antenatal  cheek up, correct diagnosis and treatment of associated
condition, institutional delivery and good neonatal care.
Contraception:
Rheumatic heart disease has worst outcome with advancing age due
to progressive endo myocardial changes.  Described by Cheslay 1978 so
these patients are advised to complete their family at an younger age with
1-2 years of interval. So the correct contraceptive method should be
advised whereas improper contraceptive can be life threatening as
described by Brenner 1975. Most of the patients with heart disease can be
treated as normal patients in regards to contraception - Somerville 1998. In
our study 7 patients underwent puerperal sterilisation, 1 underwent LSCS
with sterilization and 1 underwent MTP with sterilization.
Echo findings:
Ejection fraction is the fraction representing the amount of blood
pumped out of ventricle of the heart with each heart beat. It is a general
measure of the cardiac function.
In our study Echo was done for all patients, based on the ejection
fraction patients were classified in to mild, moderate and severe category
of heart disease. It was concluded from the above study that 42% of the
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maternal mortality falls under severe category, 42% falls under moderate
category and 16% falls under mild category.
Maternal Mortality:
Maternal mortality due to heart disease in pregnancy had incredibly
decreased over  the past 20 years but still remains an  important cause  of
maternal death in the developing  countries.
YEAR           MMR Percentage
Dorf man 1990 1.35%
Dipaklahiri et al 1995 1.35%
Koorin et al 1996 5.6%
Jacob et al 1999 15%
Deswiet 2000 3.8%`
Our study 2016 6.5%
These statistic shows that heart disease still contributes to  maternal
mortality even in the most developed countries. In U.S cardiac disease
continues to be the cause  for 10% of maternal death and this rate had
remained relatively constant during the last 50 years (East by 1998) In
developing country like  India it accounts for 8.2% of all maternal death
due to indirect causes (Mudaliar 1990)
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SUMMARY
The study was conducted in Tirunelveli Medical College Hospital
during the period June 2015 to July 2016. There were 7830 deliveries.
Among this, 107 mothers were complicated by  cardiac disease, giving us
incidence of 1.25% concordent with the reports from other studies.
 94.4% were booked and 5.6% were un booked antenatal  cases
 60%  belonged to class IV and V socioeconomic  status with poor Medical
care, nutritional status  anaemia and infection.
 7.4% were undiagnosed before pregnancy ,92.52%  were diagnosed prior
to pregnancy. Of these, only 80% were receiving regular antenatal care and
20% who were irregular had poor fetomaternal  outcome in the study
 49.5% of patients had RHD and 32.7% patients had CHD. With
improvement in health and hygiene, the incidence of RHD has come down.
Of the 35 patients with CHD,  ASD is the leading cause and they  had a
good maternal outcome. All newborns were screened for CHD and found
that there was no congenital heart diseases in the off springs of mother with
CHD.
 Of the 53 RHD case, MS is the most common. RHD patients had more
complications like CCF acute pulmonary oedema atrial fibrillation
embolism & maternal mortality.
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 Of the 26 surgically corrected cases, except 2 cases all other cases had
good fetomaternal outcome. One patients had SBE. She was booked and
delivered outside and developed embolic manifestation like hemiplegia.
 34% of the patients were anaemic which correlate with the incidence of
general population. The high incidence of anaemia  even among the
booked patients showed the poor compliance of taking oral iron. This could
be improved by parenteral  iron therapy. Severe anaemia should be
corrected with blood transfusion.
 Over 72.5% of the patients had vaginal  delivery  with liberal use  of
prophylactic  forceps.
 29.5% of the patients had LSCS.
 Over all perinatal outcome was good and 11% was preterm which
correlated with general population incidence.
Perinatal mortality is only one due to RDS.
 As RHD is a progressive disease with worst prognosis with advancing age
.Contraception  or sterilization  was advised
 Maternal mortality – 7 patients, can still be reduced by educating the
importance of good regular  antenatal care and limitation of family size
 The fear of cardiac surgery is more in our patients. So they need proper
counselling and they should be encouraged to undergo cardiac surgery, if it
is indicated even during pregnancy.
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CONCLUSION
The medical, surgical and obstetrical  care of a pregnant cardiac
patient is  considerably a difficult task. The prognosis of the patient
depends on
 Age, parity and socioeconomic status
 Functional cardiac capacity
 Other associated aggravating complications
 Quality of Medical Surgical and obstetrical care provided.
Once pregnancy is confirmed, a multi-disciplinary approach with a team of
obstetrician, cardiologist, cardiothoracic surgeon, anaesthetist good
nursing care and social care provide the good chance  to carry the
pregnancy to a successful outcome.
Thus as Francois mauricean (1966) rightly puts in “A Pregnant
woman is like a ship on a stormy sea and a good pilot in charge must guide
her with prudence if she is to avoid a ship wreck”.
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Name:
Age
Sex
IP.No:
UNIT:
LMP
EDD
GPALD
Booking:
Immunization :
DOA
DOD
DODIS:
1) G.A. At presentation
Associated Pregnancy
Complication
Type of Heart Disease
Anatomical lesion
N.Y.H.A.. Class
Associated factors
2) Post Obstetric Outcome
what and when
3) Past Medical History
When
Course
Quality of Care
CHD/RHD/OTHERS
Obesity/anaemia/fever/infections etc
Eventful I Uneventful
Diagnosed I Undiagnosed
4) Surgeries if any done before
Present pregnancy :
1) Effect of Pregnancy on Heart Disease
Heart failure/Arrhythmias/pulmonary edema
Management :
2) Effect of Heart Disease on Pregnancy
Pre term Labour I IUGR / SGA
Management
3) Labour Stages
First : Posture
Pain relief Methods :
Duration
Second: Duration
Prophylactic forceps I vaccum
Third Complications
Management
4) Caesarean Section Elective I Emergency
Indication
Type of Anaesthesia
Complications
Management
5) Baby : Male I Female
Birth Weight
Apgar
Pre term/Term/Postdated
IUGR
Cong Anomalies
Admission to NICU(SNN)
6) Puerperium Eventful/Uneventful
Contraceptive advice
7) Sterilization Type
Anaesthesia
When done
8)
Post operative period
Maternal Mortality
Eventful/Uneventful
9) Perinatal mortality
10) Investigations
• ..
S.No Name Age IP No Parity SES
B/U
B
Type of Heart disease Echo -finding Drugs
NYH
A St.
POA
Outcome 
of 
pregnancy
Sex of 
baby
B.              
Wt
MA
T 
Com. 
HD
Mat.
Com
Fet.
Com
Cont
1 Karpaga Selvi 24 1159 G2P1L1 III B
RHD-Severe ms mild MR                    
Mild PHT
RHD. LA5.1.MVAO.8 MS (S)  
MR(M) PHT (M)  4.1 /2.8/38%  
LVF (N)  NO AS> Trivial  TR , 
AR, TR PG 37 mmHg     EF38%  
T. Penicillin 1bd T 
aten 1/2 od , 
D.digoxin 1/2 od inj 
larix sos
II S.C EI LSCS M 3 T barrier
2 Kala 25 71764 primi IV B
RHD - MS severe, mild 
MR
Severe MS, Mild MR mild PHT            
EF54%       
T. Penicillin 1 bd T. 
Lauix 1od , T Ald 
altactone 1 od 
T.Digoxinlod
II S.C
outlet 
forceps
M 3.1 T
aneae
mia
barrier
3 Muthulakshmi 30 72563
G3P1L1
A1
IV B RHD -mild AS Mild AR
Ventricular hypertropy. Border 
line bicuipid aortic valve trivial 
AS, LVF (N)  EF 68% 4.7 
/2.8/68%          EF68%  
Not on drugs I S.C
Ele rpt 
LSCS- Pre- 
LSCS
M 2.8 T barrier
4 Thiravida selvi 25 76406 G2P1L1 IV B
RHD -Severe MS Mild AR 
/ Mild PHT
Severe MS. MVA 0.8 CM NO 
MR - AR -AS Mild TR Mod PHT                                     
EF54%  
T. Peuicillin 1 bd t. 
lasix 1/2 od t. Aten 1
bd
I S.C
L.N. with  
epi 
M 2.9 T barrier
5 Santhana mari 22 4405 primi III B CHD -VSD
Smell residual  VSD 4 mm NO 
PHT  LVF (N) EF 67% Lt to rt 
shut                           EF 67%
Not on drugs I S.C L.N.C EPI F 3 T
Rh-
ve
barrier
6 Sathiya 20 21390 primi III B CHD -ASD 
Smell  OS ASD with lt to rt shunt    
EF 68%
Not on drugs I S.C L N M 1.6 P.T barrier
7 Velammel 20 56545 primi V B RHD /MR-MS
S/P MVR Disc movement seen 
gradient across prosthetic MV PG 
32/93 Mild MR mild AR, No AS , 
Mild TR TR PG 52 mmHg mod 
sev  PHT? Prosthetic valve 
obstrucion EF 64% 
inj. Heparin     
inj.lasix
IV
Un 
delive
red
pul. 
Oed
ma, 
CCF
8 Veerammal 24 4040 primi III B
CHD OS ASD with (M) 
PS/PR
Smell os   ASD  with  lt to rt 
shunt   mild  PS/ PR            EF 
56%
Not on drugs I S.C
vaccum 
extraction
F 28 T
Hypo
thyroi
d 
barrier
9 Selva Vadivu 26 73839 primi III B
CHD TA with VSD single 
ventricle
single ventricle of LV with 
rudimentry rt ventricle holm's 
heart rt ventricle giving rise to 2 
arteries , aorta connected to LV 
through large VSD PA is atretic 
tricuspid atresia , single ventricle 
VSD ,LVF (N) LT AV valve  
regurgitation IAS intect (MRI)  
EF 50%
Not on drugs II S.C
Eme LSCS - 
CPD II
F 3.2 T barrier
10 Muthulakshmi 25 51231 G2A1 IV B RHD -MS -MR
RHD -Mod. MS trivial MR /AR/ 
Mod PHT MV 1.38 cm PHT 1.53 
cm2   EF 58% 
T. Penicillin 1bd T 
Aten 1/2 od , 
D.digoxin 1/2 od inj 
larix sos
I S.C LN M 1.6 PT
PRO
M
RDS barrier
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11 Priskilla      27 217 primi III B
RHD -(S) MS MILD AR -
TR PHT
sev mitral restenosis AML PML  
thickened ,PML leaflet calcified 
MVA 0.8 cm (N) LVF 3.6 /2.2 
/28% LA 3.8 cm MG 18mm Hg 
PG 27 mm Hg (M) TR , TR PG 
52mm Hg Mild AR ,no As Mod 
PHT ,No LV clots IVS intact  EF 
28%
T. Penicillin 1bd T inj 
lasix inj Heparin 
Ionoprop, T. 
Ivabridona tds  
D.digoxin 1/2 od 
IV
outlut 
forceps 
IUD
M 1.5 PT
severe 
PHT/ 
puloe
dma
IUD
12
Muthu Mangala 
Sundari
22 46893 primi IV B RHD -MS(S) M(MR) PHT
Severe  MS mild (MR) mod PHT 
EF38%
T.aten T. Penicillin I S.C
Eme   
LSCS - 
Failed indu
M 3 T barrier
13 Maheswari 22 5733 G2P1L1 III B CHD VSD
Perimembranous VSD closuure 
done trivial TR PG 23 mm Hg (N)  
biventricular function 3.6 /2.2 
/60%   EF 60%
Not on drugs I S.C LN M 1.8 T
anae
mia
SGA CuT
14 Senbagavalli 20 5680 primi IV B
RHD -MS (S)/ 
MR/TR/PHT
AML PML thickened 
PML,Mobility restricted ,LA 4.2 
cm dilated 2 clots 1.4 X 1 
cm,0.8X0.5 cm mobile clot in LA 
appendage MVA 0.9 cm MVA 
mean PG 20 mm hg AV thickened 
NO AS NO AR TR sev PHT TR 
PG 56 mm hg 3.5 /2.5/56% LVF 
(N)   EF 56%
INJ heparin for 5 days 
after oral 
anticoagulant , T. 
pencillin T. 
metoprolol 
II
LN with   
Epi 
delivered 
outside  ref 
as ? CVT
F 3 T
CVA - 
embol
ic 
stroke
15 Mutharanam    27 55757 G3P2L2 IV B RHD -MS(S) -MR /PHT
Severe MS ,MVO 0.9 cm Mild 
MR , severe PHT   EF 26%
T. Penicillin 1bd T 
aten 1/2 od , 
D.digoxin 1/2 od inj 
larix sos
IV Rpt  LSCS M 1.6 PT
anae
mia
CLF
16 Muthulakshmi 25 31280 G2A1 III B RHD - MS /MR/AR
mod MS ,MVA 1.38 cm PHT 
1.53 cm2 trivial MR/AR   EF 
42% 
T. Penicillin ,T. aten , 
T. lasix
II S.C
outlet 
forceps
M 2.4 T barrier
17 Vallimayil 31 2065 G2A1 III B RHD -MS
mitral restenosis (severe) MVO .8 
cm mild TR PG 40 mm hg AML 
PML thickened & tips calcified 
(N) LVS dysfunction   EF65% 
T. Penicillin 1bd T inj 
lasix inj Heparin 
Ionoprops, D.digoxin 
1/2 od ,inj morphine
IV
un 
delivered
pul 
oema 
severe 
PHT 
18 Essakkiammal 31 38684 primi III B RHD -TR
Trival TR (N) LV   function  EF 
70%
T. aten I S.C
vaccum 
extraction
M 2.4 T
Rh-
ve
barrier
19
Selva Mari 
Paripuranam
27 36528 G3P1L0 IV B
previous peripartum 
caciomyopathy
LVS function (N)   EF52% Not on drugs II S.C Ele   LSCS M T barrier
20 Arokiya merry 24 1159 G2P1L1 III B RHD - MS /MR/AR
Tachycardica + , LA 5.1 MVA 0.8 
cm MS (S) mild MR ,trivial AR 
trivial TR , NO AS mild PHT 
LVF (N) 4.1/28/30% TRPG 37 
mmhg  EF 30%
T. Penicillin 1bd T 
aten 1/2 od , 
D.digoxin 1/2 od inj 
larix sos
II S.C
Ele LSCS - 
Pre LSCS
M 3 T
Rh-
ve
barrier
S.No Name Age IP No Parity SES
B/U
B
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Com
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Cont
21 Mari selvi 23 415051 G2P1L1 II B RHD - MS 
MS , MVO 1.8 cm2 NO 
MR/AR/AS mild TR mod PHT  
EF 48%
T. Penicillin 1bd T 
aten 1/2 od , 1/2 od inj 
larix sos
II S.C
outlet 
forceps
F 2.8 T barrier
22 Sulthana Fathima 23 57839 G2P1L1 III B RHD - MS /MR
Mild MS /MR MVA 1.4 cm NO 
AR /NO AS NO PHT  EF56%
T. Penicillin T. 
Metroprolol
I S.C Ele LSCS M 3 T barrier
23 Guruvammal 21 61420 primi IV B CHD OS-ASD
OS ASD 17 mm lt to rt shunt no 
PHT EF 46%
Not on drugs I S.C
outlet 
forceps
F 3 T
mild 
PIH
cuT
24 Mariammal 32 3909 G2P1L1 III B CHD OS-ASD
25.4/14.8/75%   RA /RV MPA 
dilated large OS ASD 23.4 mm lt 
to rt shunt mild PHT TRPG 
40mm hg no RWMA (N) LVS 
EF52%
Not on drugs I S.C
vaccum 
extraction
F 2.8 T barrier
25 Mahalakshmi 26 5733 G2P1L1 II B CHD VSD
Perimembranous VSD closuure 
done  TR PG 24 mm Hg (N)  
biventricular function 3.5 /2.4 
/64%   EF 64%
Not on drugs I S.C LN M 2.7 T st
26 Vasuki 23 21018 primi IV B RHD AS AR
No RWMA (N) LVF 1.4 /3.4 /1.8 
/78% concentric lt ventricular 
hypertrophy  EF78% 
T. aten  T. penicilin I S.C
OUTLET 
FORCEPS
M 2.6 T barrier
27 Pitchai ammal 34 42101 G4P3L3 IV B MVPS with trival MR
Mitral valve prolapse with trivial 
MR EF70% 
Not on drugs I S.C LN M 1.9 PT
GDM  
on  
meal 
plan 
poly 
hydro
mnio
s 
RDS barrier
28 Sridevi 25 14381 primi IV B Trivial TR MR - RHD Trivial TR/MR no PHT EF 80% Not on drugs I S.C
Emg LSCS- 
F.D
F 2.9 T MAS cuT
29 Jothi 28 21032 primi III B RHD severe MS
Severe MS MVO 0.9Cm PHD EF 
56%
T. Penicillin, T.Lasix, 
T.Aten
II S.C
LN with 
EPI
F 2.7 T barrier
30 Suseela 22 21643 primi IV B MVPS/MR
Mitral valve prolapase with trivial 
MR EF 68%
Not on drugs I S.C Emg LSCS F 3.4 T MRO cuT
31 Gomathi 24 31624 primi III B CHD ASD/Mild TR
Small OS ASD with lt to rt shunt 
TR EF 52%
Not on drugs I S.C
Emg  
LSCS - 
F 3.8 T
Rh-
ve
cuT
32 Shanmuga Priya 28 61314 G2P1L1 IV B RHD MS/MR
Modrate MS / Tivial MR mild 
PHT EF 58%
T. Penicillin T. 
Metroprolol
I S.C
LN with 
EPI
M 2.7 T barrier
33 Gayathiri 23 21324 G2P1L1 IV B CHD VSD 
Small VSD with prominent lt to 
Rt shunt EF70%
Not on drugs I S.C LN F 2.3 T barrier
34 Munniyammal 26 43216 primi IV B MVP / AR
Mitral valve prolapse with mild 
AR EF 62%
Not on drugs I S.C Emg LSCS M 2.8 T MAS barrier
35 Ambika 24 54312 primi IV B CHD ASD
OS ASD small with lt to rt shunt 
with mild PR EF58%
Not on drugs II S.C
LN with 
EPI
M 2.6 T cuT
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36 Megala 27 41217 G2P1L1 V B RHD MS/MR
Mild MS MR No PHD (N) LVF 
3.8/26/68% EF68%
T. Penicillin T. 
Metroprolol
I S.C
Ele. Rpt. - 
LSCS
M 3 T barrier
37 Mery 26 36514 G2P1L0 IV B MVPS MR TR 
Mitral valve prolapse with mild 
TR / Mild MR EF 60%
Not on drugs II S.C
Vaccum 
Extraction
F 3.1 T
GDM 
on 
meal 
plan 
barrier
38 Veeralaksmi 25 11719 G2P1L1 V B RHD - AS AR
Tachycardica + no RWMA (N) 
LVF 1.3 /3.9 /1.9 /83% 
Concentric lt ven.hypertrophy 
,AUG4.6 / 87 MA PG  3.2 /48  
EF 83%
Not on drugs II S.C
OUTLET 
FORCEPS
F 2.5 T
anae
mia
barrier
39 Shanmuga Vadivu 23 14923 primi IV B RHD - MS
MS-MOD MVO 1.3 CM Medial 
commisure fibrosed lat .com.free 
MRH aortic valve thickened mild 
AR mild PHT TRPG 414 mm hg 
4.6 /2.7/70%  LVF (N)  EF 70% 
T. Penicillin 1bd T 
aten 1/2 od , 
D.digoxin 1/2 od inj 
larix sos
II S.C Eme  LSCS F 2.5
LA
TE 
PT
cuT
40 Angalaswari 25 15458 G2P1L1 IV B RHD - MR AR
AML PML thickened MVO 
AML.4 .4/2.8 /63 NO RWMA (N) 
LVF AR NO AS MR EF %
T. Penicillin 1bd I S.C
outlet 
forceps
M 2.6 T
anae
mia
st
41 Mariammal 32 18663 G2P1L1 III B CHD ASD 
large 2.5 cm ASD , Mild PHT 
RA/RV dilated (N) LVF lt to rt 
shunt TRPG 38 mmhg   EF56%
Not on drugs I S.C
out let 
forceps
F 2.8 T  cuT
42 Rajeswari 27 7373 G2A1 IV B RHD - MS MR
severe MS LA 4.5 cm LV dia 4.4 
/2.9/64 %  prosthetic valve in 
mitral position MG 17mmhg PG 
22mm hg MR + AV thickened 
mild AR no AS TRPG 58 mmhg 
Mod PHT   EF64%
T. Penicillin 1bd T 
aten 1/2 od , 
D.digoxin 1/2 od inj 
larix sos
IV Eme LSCS - F T CCF barrier
43 Shanmuga thai 30 8704 primi IV B CHD ASD 
ASD clocure 3.4 /2.3/52% no RW 
MA RA/LA dilated mild PHT (N) 
LVF EF52%
I S.C
LN with 
EPI
M 2.3 T
anae
mia
RDS cuT
44 Prabha 23 2319 G2A1 III B CHD ASD 
ASD  with bidirectional shunt 
severe PHT  EF 61 %
T. lasix I MTP MVA Done
45 Parthasarathy 20 6839 G2P1L0 IV B RHD - MR AR
mild MR /trivial AR mild PHT 
(N) LVF 3.8 /26 /70 % TRPG 30 
mm hg EF 70%
T. Penicillin 1bd T 
aten 1/2 od , 
D.digoxin 1/2 od inj 
larix sos
I S.C
outlet 
forceps
M 2.8 T barrier
46 Karpagam 27 1644 G2P1L1 III B RHD - MS MR
mild MS MR MVA 1.6 cm No 
AR AS NO PHT 3.8 /28/72%  
EF72%
T. Penicillin T. 
Metroprolol
I
Rpt ele 
LSCS - Pre 
LSCS
F 3 T
hypot
hyroi
d
st
47
Mymoon 
Rabiyath Bazeera
20 4381 primi III B CHD ASD 
smell OS ASD with lt to rt shunt   
EF 62%
Not on drugs I s.c
L.N with 
epi
M 2.9 T cuT
48 Subbulakshmi 25 6066 primi III B RHD - MS/MR mild MS  mild MR  Ef 50% T. Penicillin 1bd I S.C
OUTLET 
FORCEPS
F 3 T cuT
S.No Name Age IP No Parity SES
B/U
B
Type of Heart disease Echo -finding Drugs
NYH
A St.
POA
Outcome 
of 
pregnancy
Sex of 
baby
B.              
Wt
MA
T 
Com. 
HD
Mat.
Com
Fet.
Com
Cont
49 Subha 33 5144 G2P1L1 III RHD - severe   MR 
severe MS /MOD MR /severe 
PHT 0.9 cm TRPG 72mmhg (N) 
LVF LA RA RV dilabed no 
obvious clot AML PML thickened 
mod TR Ef 42%
T. Penicillin 1bd T 
aten 1/2 od ,  1/2 od 
inj larix sos
I
MTP 
Advis
ed by 
cardio
logist
MVA done T
SEVE
RE 
PHT 
with 
MOD
S
50 Selva Sigameni 32 8663 G2P1L1 IV B ASD 
large 2.6 cm ASD , Mild PHT 
RA/RV dilated (N) LVF lt to rt 
shunt TRPG 38 mmhg   EF54%
Not on drugs II S.C
LN with  
Epi
F 2.8 T
Rh-
ve 
,hypo
thyroi
d
barrier
51 Vijaya 24 3141 P1L1 III RHD - MS MR
SEVERE MR severe PHT post 
MVR study MV prosthesis seen 
No paravalvular leak (N) LVF 
EF66%
T. Penicillin 1bd T inj 
lasix inj Heparin 
Ionoprops,   D.digoxin 
1/2 od  inj mannitol 
T.ASA, T.atorvastatin
IV
delivered 
outside lses
infecti
ve 
endoc
arditis 
cardio
embol
istrok
e
52 Christy 35 21660
G3P2L1
A1
III B RHD - MS MR AR
SEVERE MS mod MR mild AR 
mild PHT mild pericardial 
effusion4.8/3.2/64%  TRPG 32 
mmhg EF64%
T. Penicillin 1bd T 
aten 1/2 od ,   inj larix 
sos
II S.C
Rpt  Ele 
LSCS - 
F 2.8 T barrier
53 Valliammal 36 31414 G2P1L1 IV B RHD - MS MR 
MVA  planimetry 1.6 cm mild 
M<S mod Mrno PHT AV (N) MG 
4.9mm hg EF52%
T. Penicillin T. 
Metroprolol
I S.C
Rpt Emg 
LSCS - 
M 2.7 T st
54
Rani Koperum 
Devi
36 31154 primi IV B CHD- PDA
5.1 /3.5 58% no RWMA (N) LVF 
s/p PDA closure , no residual 
shunt MPA 30 No PHT   EF 58%
Not on drugs I S.C
LN with  
EPI
M 2.8 T
mild 
PIH
barrier
55
Shanthana 
Lakshmi
26 29967
G3P1L0
A1
V B CHD- VSD
large VSD 1.1 cm subaortic VSD 
with predominent lt to rt shunt LV 
dilatation PG 41 mm hg 0.7 
/4.1/0.9/2.3 /72% no RWMA (N) 
MPA 2.6 cm mild TR TRPG 
61mmhg severe hg  EF74%
Inj lasix II S.C
LN with 
Epi 
F 3 T barrier
56 Uma 23 32318
G3P1L1
A1
III B CHD- ASD
OS ASD 24 mm lt to rt shunt no 
PHT mild TR  TRPG  EF 68%
Not on drugs I S.C
vaccum 
extraction
M 2.8 T st
57 Aayyammal 28 25260 primi III RHD MS
(N) functioning mitral prosthesis  
EF68%
INJ heparin, 
T.Warfarin
I S.C LN M 2.1 T SGA barrier
58 Sharmila 19 6144 primi IV B CHD bicuspid AV 
AV - septal cusp fusut bicuspid 
AV othere (N) ESV 77.37, EF 
64% 
Not on drugs I S.C
outlet 
forceps
M 2.7 T
aneae
mia
barrier
S.No Name Age IP No Parity SES
B/U
B
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NYH
A St.
POA
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of 
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MA
T 
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Mat.
Com
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59 Kalai Selvi 21 21315 P1L1 V B PPCM
LA 3cm severe lt ventricular 
systolic dysfunction  EPSS 1.9 cm 
MR 2+ Gr III LVDD mild TRPG 
36mmhg TAPST 1.2 cm ,rt 
ventricular dysfunction , no 
clot,mild PE EF92%
T. Lasix T.carvedilol, 
T. alsactone 
T.enalapril T.digoxin
IV
LSCS done 
21 days 
back -
TVMCH
F barrier
60 Sankareswari 35 19736 G3P2L1 V B PPCM
LV dimension4.6 /3.2/24% LV 
sys. dysfunction , mild PE TRPG 
34mmhg mild PHT NO LA clots  
EF24% 
T. Penicillin 1bd T inj 
lasix inj  T. 
Ivabridona tds  
D.digoxin 1/2 od 
IV S.C
LN with  
EPI
F 3.2 T
pulmo
nary 
oedm
a
barrier
61 Saranya 32 18641 P1L0 III B PPCM
LV demension 4.7 /3.7/49% mild 
global hypokinesia of LV mod LV 
syst .dysfunction MRH Gr I 
LVDD , trace PE mild TR TRPG 
30mmhg mild No LA clot  
EF45%
T. Lasix T.cirvedilol 
T. alsactone 
T.enalapril T.digoxin
III
Hystrotomy 
done 
outside 
M
800
gms
PT
chron
ic HT
IUD
62 Saritha 24 63941 primi IV B MVPS with MR
 MVP with MR mitral valve 
prolapse with trivial MR  EF70%
Not on drugs I S.C
LN with  
EPI
F 2.8 T
Rh-
ve
cuT
63 Maheswari 26 16143 primi V B CHD  ASD 
 smell OS ASD with lt to rt shunt   
EF 48%
Not on drugs
Emg LSCS-  
F.D
F 3 T barrier
64 Esakki thai 31 21320 G3P2L2 IV B RHD MR trivial MR (N) LVF EF64% Not on drugs I S.C LN M 2 T
IUG
R
cuT
65 Velammal 26 21412 P3L3 V B RHD MS MR
lt & rt  atrium ,lt  & rt ventricle 
(N) mitral valve is thickened 
MVO 0.8cm severe MS mild MR 
(N) LVF ,MG 10mmHg PG 
21mmhg EF58% 
T. Penicillin 1bd T 
aten 1/2 od , 
D.digoxin 1/2 od inj 
lasix sos
II
For 
PS
delivered 
outside 
high 
risk 
for 
anaest
hesia 
barrier
66 Sankari 29 14315
G3P1L1
A1
III B CHD bicuspid AV 
congenital bicuspid AV mild AS 
No resting RWMA (N) NO PE  
EF65%
Not on drugs I S.C LN M 1.8 PT
PPR
OM
RDS/ 
expir
ed
barrier
67 Manjula 24 1031 primi IV B RHD MS MR
mild MS/MR/MVA 1.3 cm 
Ef60%
T. Penicillin T. 
Metroprolol
I S.C Emg LSCS M 3 T barrier
68 Vanitha 21 7431 primi V B CHD ASD 
large 2.6 cm ASD mild PHT 
RA/RV dilated  (N) LVF lt to rt  
shunt Ef 64% 
Not on drugs II S.C
LN with 
EPI
F 2.6 T barrier
69 Geetha 20 8012 G2A1 IV B RHD  MR AR
mild MR mild AR mild PHT (N) 
LVF 3.7/24/3/68   EF 68% 
T. Penicillin 1bd T 
aten 1/2 od , 
D.digoxin 1/2 od inj 
larix sos
II S.C
vaccum  
extraction
F 2.4 T cuT
70 Sangetha 30 25764
G3P1L1
A1
IV B CHD PDA 
normal LVF NO RWMA s/p  
PDA closure No residual shunt 
MPA 28 No PHT 4.6/3.4/60%   
EF60%
Not on drugs I S.C
LN with  
EPI
M 2 PT
hypo 
thyroi
d 
barrier
71 Revathi 28 28612 G2P1L1 IV B MVPS-MR
mitral valve prolapse with trivial 
MR normal LVF EF60% 
Not on drugs I S.C
LN WITH  
EPI
F 3.1 T st
S.No Name Age IP No Parity SES
B/U
B
Type of Heart disease Echo -finding Drugs
NYH
A St.
POA
Outcome 
of 
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Sex of 
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B.              
Wt
MA
T 
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72 Esakki Selvi 30 8684 primi IV B RHD TR trivial TR   normal LVF EF74% T. Aten I S.C
Emg LSCS 
-
F 2.7 T
anae
mia
cuT
73 Visalam 23 7312 G2P1L1 V B RHD AR MR
mild MR AR No AS mild PHT 
(N) LVF 4.2 /30/70% TRPG 36 
mmhg EF70%
T. Aten  T. penicilin II S.C LN M 2.1 PT cuT
74 Kalai Rani 26 6413 G2P1L1 III B RHD MS
normal functioning mitral 
prosthesis   EF76%
T. warfarin & Inj 
.heparin
I S.C LN M 2.8 T barrier
75 Jeykalai 25 21381 primi IV B RHD MS MR
severe MS mod MR Mod PHT 0.9 
cm TRPG 60 mmhg 3.8/2.7/60% 
(N) LVF EF 60%
T. Penicillin 1bd T 
aten 1/2 od , 
D.digoxin 1/2 od inj 
larix sos
II S.C LN F 1.8 T
anae
mia
SGA barrier
76 Abirami 26 4391 primi III B RHD -MS MR
mild MS MR MVA 1.8 cm No 
AR AS NO PHT 4.2 /28/70%  
EF70%
T. Penicillin T. 
Metroprolol
I S.C
Emg  
LSCS -
F 3.2 T barrier
77 Malar 19 24310 primi IV B MVPS-PR
mitral valve prolapse with PR 
normal LVF EF65% 
Not on drugs I S.C
Emg  
LSCS 
breech In 
labour
M 2.9 T
Rh-
ve
cuT
78 Aanathi 25 3104 G2P1L1 IV B CHD VSD
Perimembranous VSD closuure 
done   3.6 /2.4 /64%   EF 64%
Not on drugs I S.C
outlet 
forceps
F 3.5 T st
79 Rajalakshmi 24 21810 primi III B RHD MR
trivial MR NO PHT (N) LVF 
3.8/26/76% EF 76% 
T.aten I S.C
outlet 
forceps
M 3.2 T UTI barrier
80 Chandra 23 34501 G2P1L1 IV B MVPS with MR
mitral valve prolapse with mild 
MR normal LVF EF68% 
Not on drugs I S.C LN M 2.3 T St
81 Srimathi 23 24912 G2A1 III B CHD ASD 
OS ASD 22mm Lt to rt shunt No 
PHT Ef 62%
Not on drugs I S.C
Emg LSCS- 
MRO
F 3 T
Rh-
ve
barrier
82 Kavitha 22 18141 primi IV B CHD VSD -PS
VSD -subaortic VSDwith 
predominent lt to rt shunt mild 
PS/PR EF70% 
T.lasix II S.C
vaccum 
extraction
F 2.8 T barrier
83 Nirmala 24 31254 G2P1L1 II B RHD MS MR
mild MS MR MVO 1.6 cm No 
AR AS NO PHT   EF42%
T. Penicillin T. 
Metroprolol
II S.C
Rpt Ele 
LSCS- 
F 2.6 T barrier
84 Ramya 33 31201 G2P1L1 III B CHD PS 
bicuspid AV Septal cusps fused 
ESV 76 EF 62%
Not on drugs I S.C
OUTLET 
FORCEPS
M 3.4 T st
85 Jeba 28 41310 G3P2L2 IV UB CHD PDA 
(N) LVF No REMA PDA closure 
No residual shunt EF 62% 
Not on drugs I S.C LN M 2.3 T
anae
mia
barrier
86 Lakshmi 34 31210
G4P2L2
A1
IV _ RHD MS MR 
severe MS mod MR Severe PHT 
(N) LVF EF 54%
T. Penicillin 1bd T 
aten 1/2 od , 
D.digoxin 1/2 od inj 
larix sos
FOR 
MTP
MVA
anae
mia
barrier
S.No Name Age IP No Parity SES
B/U
B
Type of Heart disease Echo -finding Drugs
NYH
A St.
POA
Outcome 
of 
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Sex of 
baby
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Wt
MA
T 
Com. 
HD
Mat.
Com
Fet.
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87 Shanthi 19 4210 primi V _ RHD MS
severe MS MVO 0.9cm Mod MR 
/severe PHT TRPG 70mmhg (N) 
LVF EF 50% 
T. Penicillin 1bd T 
aten 1/2 od , 
D.digoxin 1/2 od inj 
larix sos
MTP 
For 
MVA cuT
88 Muthulakshmi 30 64310
G3P1L1
A1
IV B RHD MR TR 
mild MR TR  PHT (N) LVF  3.6 
/28/70% EF70%
T. Aten  T. penicilin II S.C Ele LSCS M 2.3 T barrier
89 Usharani 27 5421 G2P1L1 V B RHD MS MR 
MVA  planimetry 1.8 cm mild 
MS mod MR no PHT AV (N) 
MG 4.9mm hg EF50%
T. Penicillin T. 
Metroprolol
I S.C
vaccum 
extraction
M 2.8 T barrier
90 Rukmani 31 6221 G3P2L2 V B RHD MR 
mild MR mild PHT (N) LVF 
4/28/64%  EF 64%
T. Penicillin I S.C LN F 1.9 PT
anae
mia
cuT
91 Nandhini 27 41320 G2P1L1 V B RHD MS
MS / MVO 1.36cm trivial TR/MR 
mild PHT EF 54%
T. Penicillin T. 
Metroprolol,  T.Lasix
I S.C
LN with 
EPI
M 2.6 T barrier
92 Fathima 28 53120 G2P1L1 III B CHD VSD 
Small residual VSD no PHT (N) 
LVF lt ot rt shunt EF 70%
Not on drugs I S.C
Assisted 
breech deli.
M 2.8 T cuT
93 Susela 23 44210 primi IV B MVPS/MR
Mitral valve prolapse with mild 
MR EF 68%
Not on drugs I S.C
LN with 
EPI
M 2.8 T
mild 
PIH
barrier
94 Thenmozhi 28 31410 primi III B Ebstein anomaly
Mild TR / TR PG 40mmhg rt to lt 
shunt (N) LVF EF 36%
Not on drugs II S.C
OUTLET 
FORCEPS
F 2.6 T barrier
95 Malar 26 26174
G3P1L1
A1
IV B MPV/TR
Mitral valve prolapse with tivial 
TR EF 72%
Not on drugs I S.C
Vaccum 
Extraction
M 3.1 T
mild 
PIH
barrier
96 Amutha 28 14127 G2P1L1 IV B CHD ASD
Small OS ASD with lt to rt shunt  
EF70%
Not on drugs I S.C
Assisted 
breech deli.
M 2.6 T
Anae
mia
cuT
97 Nisha 24 11321 primi III B RHD mild MR
Mild MR / Mild PHT (N) LVF 
4/30/72% TRPG 34mmhg EF48%
T. Penicillin T. 
Metoprolol
I S.C
LN with 
EPI
F 2.4 T barrier
98 Rosemary 27 31223 G2P1L1 IV B MVPS with MR
Mitral valve prolapse with mild 
MR EF64%
Not on drugs II S.C
OUTLET 
FORCEPS
M 3.2 T cuT
99 Mydeen beevi 22 23134 primi V B CHD ASD
Large ASD 2.6cm mild PHT 
RA/RV dilated (N) LVF lt to rt 
shunt TRPG 36mmhg EF58%
Not on drugs I S.C LN F 2 T
Rh-
ve
SGA barrier
100 Sudha 24 33426 G2A1 IV B RHD MS
Mild MS /MR MVO 1.8cm NO 
AR No AS No PHD 3.6/30/52% 
EF52%
T. Penicillin T. 
Metoprolol
I S.C
LN with 
EPI
M 2.8 T barrier
101 Vanaja 29 43172 G2P1L1 V B MVPS with TR
Mitral valve prolapse 5.1/3.1/65% 
Trival TR EF65%
Not on drugs I S.C
LN with 
EPI
F 2.9 T cuT
102 Poongodi 24 32160 primi III B RHD with MS
Mod. MS Mvo 1.6cm medial 
commisure fibrosed lat. Comm. 
Free mild PHD TRPG 40mmhg 
4.2/2.8/56% (N)LVF EF56%
T. Penicillin, T.Lasix, 
T.Aten
II S.C
LN with 
EPI
M 2.7 T barrier
103 Nazeera Banu 30 31410 G3P2L2 III B MVPS/AML
MVP AML / Trivial PR (N)LVF 
EF74%
Not on drugs I S.C
OUTLET 
FORCEPS
F 3 T
GDM 
on 
Insuli
barrier
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B
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104 Vijaya 24 61320 primi IV B CHD VSD
Perimembranous VSD closure 
done TRPG 26mmhg 3.4/2.6/52% 
EF52%
Not on drugs I S.C LN M 2.5 T
Hypo
thyroi
d
cuT
105 Saraswathi 22 74121 primi III B CHD ASD/VSD
ASD /VSD closure done 
3.6/2.4/48% No RWMA mild 
PHT (N) LVF EF 48%
Not on drugs II S.C
LN with 
EPI
M 2.9 T barrier
106 GomaLa Valli 21 38142 primi III UB CHD PDA 
No RWMA (N) LVF S/P PDA 
closure no resivual shunt MPA 32 
NO PHT 4.8/3.4/56%y  EF56% 
Not on drugs I S.C
OUTLET 
FORCEPS
M 3.1 T barrier
107 Velammal 27 25110 P4L1 IV B PPCM
Global hypokinesia of LF LV 
4.3/3.7/27% sever LV dysfunction 
MRH rt ventricular dysfunction 
with TAPSE 1.2cm TRPG 
28mmhg (PHT under estimated ) 
IVC dilated 2.4cm ? PPCM ? 
Myocarditis
Ionotrops, Inj. Lasis 
IV, T.Digoxin
IV
RPT LSCS 
IUD 
DELIVER
ED 
OUTSIDE
T
ppcm/ 
pulmo
nary 
oedm
a/ 
multio
rgan 
failiur
e 
irrever
sible/ 
cardio
previ
ous 2 
IUD - 
ecla
mpsi
a
Others
CTSopinion- 
surgery after 6 
months of 
delivery
 PTM/ BMV 
done on 2012
closure done at 
10 yrs of her age
ASD Closure  
done -septo 
plasty done 11 
yrs back
MVR done 3 yrs 
back
TOF - 6 Yrs 
back corrected
BMV done on   
2014
Others
Open heart 
surgery for ms- 
1o yrs back  
VSD Closure 
done on 2010
neuro - opinion 
CT brain 
hypodense rt 
capsuloganglion 
region
CTS-CMC / 
BMC  indicated 
in II nd trimester  
review after 
delivery 
mitral valve 
surgery done 14 
yrs back
Others
CTS - 
pericardial  
patch closuru 
after delivery
VSD closuru 
done -2010
Others
subaortic 
excision done 
8yrs back
PTMc done 5 yrs 
back
MVR done -10 
yrs back
ASD Closure 
done 25.11.15
annulo palsty 
done -2004
Others
cardiologist - 
advised MTP 
CTS - closure 
after 6 month of 
delivery 
 MVR done on -
2009
CMC done -
2000
PDA Closure 
done / PIH on T. 
lebetolol
cardio - has high 
cardiac risk
MVR  done  on-
2014
Others
ASD closour  
done
CTS opinion -
closure after 
delivery 
PDA closure 
done 
Others
MVR done 10 
yrs back
Others
CMC done -4 
yrs back
MVR done
VSD clouno 
done
CTS opinion -  
clsoxure after 
delivery
Others
VSD cloune 
done
ASD (VSD ) 
cloume done
PDA  cloume 
done
CI  brain after 
stability ? 
ischemic 
encephalopathy
